NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2005. (Treatment Improvement Protocol (TIP) Series, No. 43.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs

Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs.

Show details

Appendix A: Bibliography

  1. Abbott P J, Moore B, Delaney H. Community reinforcement approach and relapse prevention: 12 and 18 month follow-up. Journal of Maintenance in the Addictions. 2003;2(3):35–50.
  2. Adinoff B. Long-term therapy with benzodiazepines despite alcohol dependence disorder: Seven cases reported. American Journal on Addictions. 1992;1(4):288–293.
  3. Ahmed A G, Salib E, Ruben S. Psychiatric disorders in first-degree relatives of patients with opiate dependence. Medical Science and Law. 1999;39(3):219–227. [PubMed: 10466316]
  4. Alderman C P, Frith P A. Fluvoxamine-methadone interaction. Australian and New Zealand Journal of Psychiatry. 1999;33:99–101. [PubMed: 10197892]
  5. Allen J P, Columbus M, eds. Assessing Alcohol Problems: A Guide for Clinicians and Researchers. National Institute on Alcohol Abuse and Alcoholism (NIAAA) Treatment Handbook Series 4. Bethesda, MD: NIAAA, 1995.
  6. Alling F A, Johnson B D, Elmoghazy E. Cranial electrostimulation (CES) use in the detoxification of opiate-dependent patients. Journal of Substance Abuse Treatment. 1990;7(3):173–180. [PubMed: 2231825]
  7. Alterman A I, Rutherford M J, Cacciola J S, McKay J R, Boardman C R. Prediction of 7-months methadone maintenance response by four measures of antisociality. Drug and Alcohol Dependence. 1998;49(3):217–223. [PubMed: 9571386]
  8. Amass L, Kamien J B, Mikulich S K. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug and Alcohol Dependence. 2000;58:143–152. [PubMed: 10669065]
  9. Amass L, Kamien J B, Mikulich S K. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug and Alcohol Dependence. 2001;61:173–181. [PubMed: 11137282]
  10. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human breast milk. Pediatrics. 1983;72(3):375–383. [PubMed: 6889044]
  11. American Academy of Pediatrics Committee on Drugs. Neonatal drug withdrawal. Pediatrics. 1998;101(6):1079–1088. [PubMed: 9614425]
  12. American Association for the Treatment of Opioid Dependence (AATOD). Expert Panel Clinical Guidelines on LAAM. New York: AATOD, n.d. www​.aatod.org/factsheet3.htm[accessed May 3, 2004].
  13. American Association of Suicidology. About Suicide: Understanding and Helping the Suicidal Person. Washington, DC: American Association of Suicidology, n.d. www.suicidology.org/displaycommon.cfm?an=2 [accessed May 3, 2004].
  14. American Methadone Treatment Association, Inc. The Joy of Being Normal[videotape]. Silver Spring, MD: Danya International, Inc., 2000.
  15. American Psychiatric Association. Practice Guidelines for the Treatment of Patients With Substance Abuse Disorders: Alcohol, Cocaine, Opioids. Washington, DC: American Psychiatric Association, 1995.
  16. American Psychiatric Association. American Psychiatric Association Practice Guidelines. Washington, DC: American Psychiatric Association, 1996.
  17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
  18. American Society of Addiction Medicine. Public policy statement on methadone treatment. Journal of Maintenance in the Addictions. 1997;1(1):125–126.
  19. Anderson M W, Sharma K, Feeney C M. Wound botulism associated with black tar heroin. Academic Emergency Medicine. 1997;4:805–809. [PubMed: 9262701]
  20. Anglin M D. The efficacy of civil commitment in treating narcotic addiction. In: Leukefeld, C.G., and Tims, F.M., eds. Compulsory Treatment of Drug Abuse: Research and Clinical Practice. NIDA Research Monograph 86. NIH Publication No. 94-3713. Rockville, MD: National Institute on Drug Abuse, 1988, reprinted 1994, pp. 8–34.
  21. Appel P W, Joseph H, Kott A, Nottingham W, Tasiny E, Habel E. Selected in-treatment outcomes of long-term methadone maintenance treatment patients in New York State. Mount Sinai Journal of Medicine. 2001;68(1):55–61. [PubMed: 11135507]
  22. Appel P W, Joseph H, Richman B L. Causes and rates of death among methadone maintenance patients before and after the onset of the HIV/AIDS epidemic. Mount Sinai Journal of Medicine. 2000;67(56):444–451. [PubMed: 11064496]
  23. Archie C. Methadone in the management of narcotic addiction in pregnancy [editorial] Current Opinion in Obstetrics and Gynecology. 1998;10(6):435–440. [PubMed: 9866009]
  24. Astemborski J, Vlahov D, Warren D, Solomon L, Nelson K E. The trading of sex for drugs or money and HIV seropositivity among female intravenous drug users. American Journal of Public Health. 1994;84:382–387. [PMC free article: PMC1614821] [PubMed: 8129052]
  25. Auriacombe M. Lagier G. Mallaret M. Thirion X. Strain E C. Clarke H W. French experience with buprenorphine. In: Dewey, W.L., and Harris, L.S., eds. Problems of Drug Dependence, 2002: Proceedings of the 64th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. NIDA Research Monograph. 183. NIH Publication No. 03-5339. Rockville, MD: National Institute on Drug Abuse, 2003, pp. 134–141.
  26. Baffis V, Shrier I, Sherker A H, Szilogyi A. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Annals of Internal Medicine. 1999;131(9):696–701. [PubMed: 10577333]
  27. Baker J G, Rounds J B, Carson C A. Monitoring in methadone maintenance treatment. International Journal of the Addictions. 1995;30(9):1177–1185. [PubMed: 7591356]
  28. Ball J C, Lange W R, Myers C P, Friedman S R. Reducing the risk of AIDS through methadone maintenance treatment. Journal of Health and Social Behavior. 1988;29(3):214–226. [PubMed: 3241064]
  29. Ball J C, Ross A. The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome. New York: Springer-Verlag, 1991.
  30. Barry C. Afraid of methadone: Over-reaction to overdoses in Portland means tighter rules on a drug universally accepted to treat opiate addictions. The Portland Phoenix, September 27, 2002. www​.portlandphoenix.com[accessed May 3, 2004].
  31. Baskin L B, Morgan D L. Drugs detected in patients suspected of acute intoxication. Texas Medicine. 1997;93(9):50–58. [PubMed: 9754396]
  32. Batki S L, Gruber V A, Bradley J M, Bradley M, Delucchi K. A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. Drug and Alcohol Dependence. 2002;66(3):283–293. [PubMed: 12062463]
  33. Beauchamp T L, Childress J F. Principles of Biomedical Ethics, 5th ed. New York: Oxford University Press, 2001.
  34. Beck A T, Wright F D, Newman C F, Liese B S. Cognitive Therapy of Substance Abuse. New York: Guilford Press, 1993.
  35. Beck M, Mirmohammadsadegh A, Franz B, Blanke J, Hengge U R. Opioid receptors on white blood cells: Effect of HIV infection and methadone treatment. Pain. 2002;98(12):187–194. [PubMed: 12098631]
  36. Belding M A, Iguchi M Y, Morral A R, Husband S D. MMPI profiles of opiate addicts: Predicting response to treatment. Journal of Personality Assessment. 1998;70(2):324–339. [PubMed: 9697334]
  37. Bell J. Delivering effective methadone treatment. In: Ward, J.; Mattick, R.P.; and Hall, W., eds. Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Amsterdam: Harwood Academic Publishers, 1998, pp. 161–175.
  38. Bell J. Quality improvement for methadone maintenance treatment. Substance Use & Misuse. 2000;35(1214):1735–1756. [PubMed: 11138706]
  39. Bell J, Zador D. A risk-benefit analysis of methadone maintenance treatment. Drug Safety. 2000;22(3):179–190. [PubMed: 10738842]
  40. Belluck P. Methadone, once the way out, suddenly grows as a killer drug. New York Times, February 9, 2003, p. 1.
  41. Berghella V, Lim P, Hill M K, Cherpes J, Chennat J, Kaltenbach K. Maternal methadone dose and neonatal withdrawal. American Journal of Obstetrics and Gynecology. 2003;189(2):312–317. [PubMed: 14520184]
  42. Berson A, Gervais A, Cazals D, Boyer N, Durand F, Bernuau J, Marcellin P, Degott C, Valla D, Pessayre D. Hepatitis after intravenous buprenorphine misuse in heroin addicts. Journal of Hepatology. 2001;34:346–350. [PubMed: 11281569]
  43. Bickel W K, Amass L. The relationship of mean daily blood alcohol levels to admission MAST, clinic absenteeism and depression in alcoholic methadone patients. Drug and Alcohol Dependence. 1993;32(2):113–118. [PubMed: 8389689]
  44. Bickel W K, Amass L, Higgins S T, Badger G J, Esch R A. Effects of adding behavioral treatment to opiate detoxification with buprenorphine. Journal of Consulting and Clinical Psychology. 1997;65(5):803–810. [PubMed: 9337499]
  45. Blanke R B. Accuracy in urinalysis. In: Hawks, R.L., and Chiang, C.H., eds. Urine Testing for Drugs of Abuse. NIDA Research Monograph 73. Washington, DC: Supt. of Docs., U.S. Govt. Print. Off., 1986, pp. 45–53.
  46. Boatwright D E. Buprenorphine and addiction: Challenges for the pharmacist. Journal of the American Pharmaceutical Association. 2002;42(3):432–438. [PubMed: 12030630]
  47. Borg L, Broe D M, Ho A, Kreek M J. Cocaine abuse sharply reduced in an effective methadone maintenance program. Journal of Addictive Diseases. 1999;18(4):63–75. [PubMed: 10631964]
  48. Borg L, Ho A, Wells A, Joseph H, Appel P, Moody D, Kreek M J. The use of levo-alpha-acetylmethadol (LAAM) in methadone patients who have not achieved heroin abstinence. Journal of Addictive Diseases. 2002;21(3):13–22. [PubMed: 12094997]
  49. Borges G, Walters E E, Kessler R C. Association of substance use, abuse, and dependence with subsequent suicidal behavior. American Journal of Epidemiology. 2000;151(8):781–789. [PubMed: 10965975]
  50. Bovasso G B, Alterman A I, Cacciola J S, Cook T G. Predictive validity of the Addiction Severity Index's composite scores in the assessment of 2-year outcomes in a methadone maintenance population. Psychology of Addictive Behaviors. 2001;15(3):171–176. Published erratum in Psychology of Addictive Behaviors 16(1):71, 2002. [PubMed: 11563793]
  51. Braithwaite R A, Jarvie D R, Minty P S B, Simpson D, Widdop B. Screening for drugs of abuse. I: Opiates, amphetamines and cocaine. Annals of Clinical Biochemistry. 1995;32(2):123–153. [PubMed: 7785941]
  52. Branson B M. Home sample collection tests for HIV infection. JAMA. 1998;283(19):1699–1701. [PubMed: 9832003]
  53. Brazelton T B. Neonatal Behavior Assessment Scale, 2d ed. London: Spastics International Medical Publications, 1984.
  54. Brecher E M, the Editors of Consumer Reports Licit and Illicit Drugs: The Consumers Union Report on Narcotics, Stimulants, Depressants, Inhalants, Hallucinogens, and Marijuana—Including Caffeine, Nicotine, and Alcohol. Boston: Little Brown & Company, 1972.
  55. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: A systematic review of the literature and meta-analysis. British Journal of Obstetrics and Gynaecology. 1998;105:836–848. [PubMed: 9746375]
  56. Brooner R, Kidorf M, King V, Beilenson P, Svikis D, Vlahov D. Drug abuse treatment success among needle exchange participants. Public Health Reports. 1998;113(Suppl. 1):129–139. [PMC free article: PMC1307735] [PubMed: 9722818]
  57. Brooner R K, Greenfield L, Schmidt C W, Bigelow G E. Antisocial personality disorder and HIV infection among intravenous drug abusers. American Journal of Psychiatry. 1993;150(1):53–58. [PubMed: 8417580]
  58. Brooner R K, Kidorf M. Using behavioral reinforcement to improve methadone treatment participation. Science & Practice Perspectives. 2002;1(1):38–49. [PMC free article: PMC2851064] [PubMed: 18567965]
  59. Brooner R K, King V L, Kidorf M, Schmidt C W Jr, Bigelow G E. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Archives of General Psychiatry. 1997;54(1):71–80. [PubMed: 9006403]
  60. Brown H L, Britton K A, Mahaffey D, Brizendine E, Hiett A K, Turnquest M A. Methadone maintenance in pregnancy: A reappraisal. American Journal of Obstetrics and Gynecology. 1998;179(2):459–463. [PubMed: 9731853]
  61. Brown L S, Ajuluchukwu D C, Gonzalez V, Chu A F. . Medical Disorders of Female Intravenous Drug Abusers in Methadone Maintenance Treatment Programs. NIDA Special Monograph. Rockville, MD: U.S. Department of Health and Human Services, 1992.
  62. Bucceri A, Luchini L, Rancilio L, Grossi E, Ferraris G, Rossi G, Vignali M, Parazzini F. Pregnancy outcome among HIV positive and negative intravenous drug users. European Journal of Obstetrics and Gynecology and Reproductive Biology. 1997;72:169–174. [PubMed: 9134397]
  63. Burns D N, Landesman S, Minkoff H, Wright D J, Waters D, Mitchell R M, Rubinstein A, Willoughby A. The influence of pregnancy on human immunodeficiency virus type 1 infection: Antepartum and postpartum changes in human immunodeficiency virus type 1 viral load. American Journal of Obstetrics and Gynecology. 1998;178:355–359. [PubMed: 9500499]
  64. Cacciola J S, Alterman A I, Rutherford M J, McKay J R, Mulvaney F D. The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug and Alcohol Dependence. 2001;61(3):271–280. [PubMed: 11164691]
  65. Cacciola J S, Alterman A I, Rutherford M J, Snider E C. Treatment response of antisocial substance abusers. Journal of Nervous and Mental Disease. 1995;183(3):166–171. [PubMed: 7891063]
  66. Calsyn D A, Fleming C, Wells E A, Saxon A J. Personality disorder subtypes among opiate addicts in methadone maintenance. Psychology of Addictive Behaviors. 1996;10(1):3–8.
  67. Calsyn D A, Saxon A J, Barndt C. Urine screening practices in methadone maintenance clinics: A survey of how results are used. Journal of Nervous and Mental Disease. 1991;179:222–227. [PubMed: 2007893]
  68. Calsyn D A, Wells E A, Fleming C, Saxon A J. Changes in Millon Clinical Multiaxial Inventory scores among opiate addicts as a function of retention in methadone maintenance treatment and recent drug use. American Journal of Drug and Alcohol Abuse. 2000a;26(2):297–309. [PubMed: 10852362]
  69. Calsyn D A, Wells E A, Saxon A J, Jackson R, Heiman J R, Matsumoto A M. Sexual activity under the influence of drugs is common among methadone clients. In: Harris, L.S., ed. Problems of Drug Dependence: Proceedings of the 61st Annual Scientific Meeting, the College on Problems of Drug Dependence, Inc. NIDA Research Monograph 180. NIH Publication No. 00-4737. Rockville, MD: National Institute on Drug Abuse, 2000b, p. 315.
  70. Camacho L M, Brown B S, Simpson D D. Psychological dysfunction and HIV/AIDS risk behavior. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1996;11:198–202. [PubMed: 8556403]
  71. Caplan Y H, Cone E J. Drug Testing Advisory Board. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1997.
  72. Caplehorn J R, Bell J. Methadone dosage and retention of patients in maintenance treatment. Medical Journal of Australia. 1991;154(3):195–199. Published erratum in Medical Journal of Australia 159(9):640, 1993. [PubMed: 1988793]
  73. Caplehorn J R, Drummer O H. Mortality associated with New South Wales methadone programs in 1994: Lives lost and saved. Medical Journal of Australia. 1999;170(3):104–109. [PubMed: 10065120]
  74. Caplehorn J R, Hartel D M, Irwig L. Measuring and comparing the attitudes and beliefs of staff working in New York methadone maintenance clinics. Substance Use & Misuse. 1997;32:319–413. [PubMed: 9090802]
  75. Caplehorn J R, Lumley T S, Irwig L. Staff attitudes and retention of patients in methadone maintenance programs. Drug and Alcohol Dependence. 1998;52(1):57–61. [PubMed: 9788007]
  76. Caputo F, Addolorato G, Domenicali M, Mosti A, Viaggi M, Trevisani F, Gasbarrini G, Bernardi M, Stefanini G F. Services for Addiction Treatment. Short-term methadone administration reduces alcohol consumption in nonalcoholic heroin addicts. Alcohol and Alcoholism. 2002;37(2):164–168. [PubMed: 11912072]
  77. Carroll K M, Chang G, Behr H M, Clinton B, Kosten T R. Improving treatment outcome in pregnant, methadone-maintained women: Results from a randomized clinical trial. American Journal on Addictions. 1995;4(1):56–59.
  78. Carroll K M, Nich C, Ball S A, McCance E, Frankforter T L, Rounsaville B J. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: Sustained effects of treatment. Addiction. 2000;95(9):1335–1349. [PubMed: 11048353]
  79. Center for Substance Abuse Prevention. Cultural competence for social workers. In: Philleo, J., and Brisbane, F.L., eds. Cultural Competence Series. DHHS Publication No. (SMA) 95-3075. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1995.
  80. Centers for Disease Control. Perspectives in disease prevention and health promotion update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. Morbidity and Mortality Weekly Report. 1988a;37(24):377–388. [PubMed: 2836717]
  81. Centers for Disease Control. Recommendations of the immunization practices advisory committee prevention of perinatal transmission of hepatitis B virus: Prenatal screening of all pregnant women for hepatitis B surface antigen. Morbidity and Mortality Weekly Report. 1988b;37(22):341–346. www​.cdc.gov/mmwr/preview​/mmwrhtml/00000036.htm[accessed May 3, 2004] [PubMed: 2967425]
  82. Centers for Disease Control and Prevention (CDC). Core Curriculum on Tuberculosis: What the Clinician Should Know, 4th ed. Atlanta, GA: U.S. Department of Health and Human Services, CDC, Division of Tuberculosis Elimination, 2000.
  83. Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral. Morbidity and Mortality Weekly Report. 2001a;50(RR-19):1–58. [PubMed: 11718472]
  84. Centers for Disease Control and Prevention. Revised recommendations for HIV screening of pregnant women. Morbidity and Mortality Weekly Report. 2001b;50(RR-19):1–57. [PubMed: 11718472]
  85. Centers for Disease Control Prevention. Notice to readers: Approval of a new rapid test for HIV antibody. Morbidity and Mortality Weekly Report. 2002a;51(46):1051–1052. [PubMed: 12487529]
  86. Centers for Disease Control and Prevention (CDC). Reported TB Cases: United States, 1981-2001. 2001 Surveillance Slides. Atlanta, GA: U.S. Department of Health and Human Services, CDC, Division of Tuberculosis Elimination, 2002b.
  87. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines—2002. Morbidity and Mortality Weekly Report. 2002c;51(RR-6):1–84. [PubMed: 12184549]
  88. Centers for Disease Control and Prevention (CDC). Advancing HIV prevention: New strategies for a changing epidemic—United States, 2003. Morbidity and Mortality Weekly Report. 2003a;52(15):329–332. [PubMed: 12733863]
  89. Centers for Disease Control and Prevention (CDC). Frequently Asked Questions About the OraQuick Rapid HIV-1 Antibody Test. Atlanta, GA: CDC, 2003b. www​.cdc.gov/hiv/PUBS/faq/oraqckfaq.htm[accessed May 3, 2004].
  90. Centers for Disease Control and Prevention (CDC). Sexually Transmitted Disease Surveillance 2001 Supplement: Syphilis Surveillance Report. Atlanta, GA: U.S. Department of Health and Human Services, CDC, National Center for HIV, STD, and TB Prevention, 2003c.
  91. Centers for Disease Control and Prevention (CDC). Viral Hepatitis B Fact Sheet. Atlanta, GA: U.S. Department of Health and Human Services, CDC, National Center for Infectious Diseases, 2003d.
  92. Chang G, Carroll K M, Behr H M, Kosten T R. Improving treatment outcome in pregnant opiate-dependent women. Journal of Substance Abuse Treatment. 1992;9(4):327–330. [PMC free article: PMC3677856] [PubMed: 1479630]
  93. Chappel J N, DuPont R L. Twelve-step and mutual-help programs for addictive disorders. Psychiatric Clinics of North America. 1999;22(2):425–446. [PubMed: 10385942]
  94. Chasnoff I J, Hatcher R, Burns W. Polydrug and methadone addicted newborns: A continuum of impairment? Pediatrics. 1982;70(2):210–213. [PubMed: 7099786]
  95. Chasnoff I J, Schnoll S H, Burns W J, Burns K. Maternal non-narcotic substance abuse during pregnancy: Effects on infant development. Neurobehavioral Toxicology and Teratology. 1984;6(4):277–280. [PubMed: 6514088]
  96. Chatham L R, Knight K, Joe G W, Simpson D D. Suicidality in a sample of methadone maintenance clients. American Journal of Drug and Alcohol Abuse. 1995a;21(3):345–361. [PubMed: 7484984]
  97. Chatham L R, Rowan-Szal G A, Joe G W, Brown B S, Simpson D D. Heavy drinking in a population of methadone-maintained clients. Journal of Studies on Alcohol. 1995b;56(4):417–422. [PubMed: 7674677]
  98. Chaulk C P, Moore-Rice K, Rizzo R, Chaisson R E. Eleven years of community-based directly observed therapy for tuberculosis. JAMA. 1995;274(12):945–951. [PubMed: 7674524]
  99. Chawarski M C, Schottenfeld R S, O'Connor P G, Pakes J. Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug and Alcohol Dependence. 1999;55:157–163. [PubMed: 10402160]
  100. Childress A R, Ehrman R, Rohsenow D J, Robbins S J, O'Brien C P. Classically conditioned factors in drug dependence. In: Lowinson, J.H.; Ruiz, P.; and Millman, R.B., eds. Substance Abuse: A Comprehensive Textbook. Baltimore: Williams & Wilkins, 1992, pp. 56–69.
  101. Chutuape M A, Silverman K, Stitzer M L. Survey assessment of methadone treatment services as reinforcers. American Journal of Drug and Alcohol Abuse. 1998;24(1):1–16. [PubMed: 9513626]
  102. Cicero T J, Adams E H, Geller A, Inciardi J A, Munoz A, Schnoll S H, Senay E C, Woody G E. A postmarketing surveillance program to monitor Ultram® (tramadol hydrochloride) abuse in the United States. Drug and Alcohol Dependence. 1999;57:7–22. [PubMed: 10617309]
  103. Cirimele V, Kintz P, Lohner S, Ludes B. Enzyme immunoassay validation for the detection of buprenorphine in urine. Journal of Analytical Toxicology. 2003;27(2):103–105. [PubMed: 12670004]
  104. Clark H W. Dear Colleague (Letter to opioid treatment professionals). Rockville, MD: Substance Abuse and Mental Health Services Administration, July 18, 2003.
  105. Clark H W, Masson C L, Delucchi K L, Hall S M, Sees K L. Violent traumatic events and drug abuse severity. Journal of Substance Abuse Treatment. 2001;20(2):121–127. [PubMed: 11306214]
  106. Clarke J G, Stein M D, McGarry K A, Gogineni A. Interest in smoking cessation among injection drug users. American Journal on Addictions. 2001;10(2):159–166. [PubMed: 11444157]
  107. Clarke S M, Mulcahy F M, Tjia J, Reynolds H E, Gibbons S E, Barry M G, Back D J. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clinical Infectious Diseases. 2001a;33(9):1595–1597. [PubMed: 11568856]
  108. Clarke S M, Mulcahy F M, Tjia J, Reynolds H E, Gibbons S E, Barry M G, Back D J. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. British Journal of Clinical Pharmacology. 2001b;51(3):213–217. [PMC free article: PMC2015032] [PubMed: 11298066]
  109. Clemmey P, Brooner R, Chutuape M A, Kidorf M, Stitzer M. Smoking habits and attitudes in a methadone maintenance treatment population. Drug and Alcohol Dependence. 1997;44(23):123–132. [PubMed: 9088784]
  110. Coffin P O, Galea S, Ahern J, Leon A C, Vlahov D, Tardiff K. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990–98. Addiction. 2003;98(6):739–747. [PubMed: 12780362]
  111. Cohen J S. Preventing adverse drug interactions before they occur. Medscape Pharmacotherapy 1(2), 1999. www​.medscape.com[accessed May 3, 2004].
  112. Compton P, Athanasos P. Chronic pain, substance abuse, and addiction. Nursing Clinics of North America. 2003;38(3):525–537. [PubMed: 14567207]
  113. Compton P, Charuvastra V C, Ling W. Pain intolerance in opioid-maintained former opiate addicts: Effect of long-acting maintenance agent. Drug and Alcohol Dependence. 2001;63:139–146. [PubMed: 11376918]
  114. Compton P, McCaffery M. Treating acute pain in addicted patients. In: McCaffery, M., and Pasero, C., eds. Pain: Clinical Manual, 2d ed. Carlsbad, CA: Mosby, Inc., 1999.
  115. Compton P A, Ling W, Wesson D R, Charuvastra V C, Wilkins J. Urine toxicology as an outcome measure in drug abuse clinical trials: Must every sample be analyzed? Journal of Addictive Diseases. 1996;15(2):89–92. [PubMed: 8704003]
  116. Compton W M III, Cottler L B, Phelps D L, Ben Abdallah A, Spitznagel E L. Psychiatric disorders among drug dependent subjects: Are they primary or secondary? American Journal on Addictions. 2000;9(2):126–134. [PubMed: 10934574]
  117. Condelli W S. Strategies for increasing retention in methadone programs. Journal of Psychoactive Drugs. 1993;25(2):143–147. [PubMed: 8377082]
  118. Condelli W S, Dunteman G H. Exposure to methadone programs and heroin use. American Journal of Drug and Alcohol Abuse. 1993;19(1):65–78. [PubMed: 8438832]
  119. Cone E J. New developments in biological measures of drug prevalence. In: Harrison, L.D., and Hughes, A., eds. The Validity of Self-Reported Drug Use: Improving the Accuracy of Survey Estimates. NIDA Research Monograph 167. DHHS Publication No. (NIH) 97-4147. Rockville, MD: National Institute on Drug Abuse, 1997, p. 114.
  120. Cone E J, Preston K L. Toxicologic aspects of heroin substitution treatment. Therapeutic Drug Monitoring. 2002;24(2):193–198. [PubMed: 11897965]
  121. Conklin C A, Tiffany S T. Applying extinction research and theory to cue-exposure addiction treatments. Addiction. 2002;97:155–167. [PubMed: 11860387]
  122. Connaughton J F, Reeser D, Schut J, Finnegan L P. Perinatal addiction: Outcome and management. American Journal of Obstetrics and Gynecology. 1977;129(6):679–686. [PubMed: 303464]
  123. Courtwright D T. Dark Paradise: A History of Opiate Addiction. Cambridge, MA: Harvard University Press, 1982, expanded edition 2001.
  124. Courtwright D T, Joseph H, Des Jarlais D. Addicts Who Survived: An Oral History of Narcotic Use in America, 1923-1965. Knoxville, TN: University of Tennessee Press, 1989.
  125. Cowan A. Buprenorphine: New pharmacological aspects. International Journal of Clinical Practice Supplement. 2003;113:3–8. [PubMed: 12665117]
  126. Cozza K L, Armstrong S C. The Cytochrome P450 System: Drug Interaction Principles for Medical Practice. Washington, DC: American Psychiatric Publishing, Inc., 2001.
  127. Crane E. Narcotic analgesics in brief. The DAWN Report, January 2003. Rockville, MD: Office of Applied Studies, Substance Abuse and Mental Health Services Administration, 2003.
  128. Crowley T J. Research on contingency management of drug dependence: Clinical implications and future directions. In: Higgins, S.T., and Silverman, K., eds. Motivating Behavior Change Among Illicit-Drug Abusers. Washington, DC: American Psychological Association, 1999.
  129. CSAT (Center for Substance Abuse Treatment). Screening for Infectious Diseases Among Substance Abusers. Treatment Improvement Protocol (TIP) Series 6. DHHS Publication No. (SMA) 95-3060. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1993a, reprinted 1995.
  130. CSAT (Center for Substance Abuse Treatment). State Methadone Treatment Guidelines. Treatment Improvement Protocol (TIP) Series 1. DHHS Publication No. (SMA) 93-1991. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1993b, reprinted 2000, 2002.
  131. CSAT (Center for Substance Abuse Treatment). Demystifying Evaluation: A Manual for Evaluating Your Substance Abuse Treatment Program—Volume 1. DHHS Publication No. (SMA) 99-3341. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1997a, reprinted 1999.
  132. CSAT (Center for Substance Abuse Treatment). Substance Abuse Treatment and Domestic Violence. Treatment Improvement Protocol (TIP) Series 25. DHHS Publication No. (SMA) 00-3406. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1997b, reprinted 2000.
  133. CSAT (Center for Substance Abuse Treatment). Naltrexone and Alcoholism Treatment. Treatment Improvement Protocol (TIP) Series 28. DHHS Publication No. (SMA) 98-3206. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1998a.
  134. CSAT (Center for Substance Abuse Treatment). Substance Abuse Among Older Adults. Treatment Improvement Protocol (TIP) Series 26. DHHS Publication No. (SMA) 01-3496. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1998b, reprinted 2001.
  135. CSAT (Center for Substance Abuse Treatment). Substance Use Disorder Treatment for People With Physical and Cognitive Disabilities. Treatment Improvement Protocol (TIP) Series 29. DHHS Publication No. (SMA) 98-3249. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1998c.
  136. CSAT (Center for Substance Abuse Treatment). Enhancing Motivation for Change in Substance Abuse Treatment. Treatment Improvement Protocol (TIP) Series 35. DHHS Publication No. (SMA) 00-3460. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1999a, reprinted 2000.
  137. CSAT (Center for Substance Abuse Treatment). Guidelines for the Accreditation of Opioid Treatment Programs. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1999b.
  138. CSAT (Center for Substance Abuse Treatment). Treatment for Stimulant Use Disorders. Treatment Improvement Protocol (TIP) Series 33. DHHS Publication No. (SMA) 99-3296. Rockville, MD: Substance Abuse and Mental Health Services Administration 1999c.
  139. CSAT (Center for Substance Abuse Treatment). Treatment of Adolescents With Substance Use Disorders. Treatment Improvement Protocol (TIP) Series 32. DHHS Publication No. (SMA) 99-3345. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1999d, reprinted 2001.
  140. CSAT (Center for Substance Abuse Treatment). Addiction Knows No Boundaries, It's Everybody's Business: Methadone Community Education Kit. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2000a.
  141. CSAT (Center for Substance Abuse Treatment). Changing the Conversation—Improving Substance Abuse Treatment: The National Treatment Plan Initiative. DHHS Publication No. (SMA) 00-3479. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2000b.
  142. CSAT (Center for Substance Abuse Treatment). Integrating Substance Abuse Treatment and Vocational Services. Treatment Improvement Protocol (TIP) Series 38. DHHS Publication No. (SMA) 00-3470. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2000c.
  143. CSAT (Center for Substance Abuse Treatment). Substance Abuse Treatment for Persons With Child Abuse and Neglect Issues. Treatment Improvement Protocol (TIP) Series 36. DHHS Publication No. (SMA) 00-3357. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2000d.
  144. CSAT (Center for Substance Abuse Treatment). Substance Abuse Treatment for Persons With HIV/AIDS. Treatment Improvement Protocol (TIP) Series 37. DHHS Publication No. (SMA) 00-3410. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2000e.
  145. CSAT (Center for Substance Abuse Treatment). OxyContin®: Prescription drug abuse. CSAT Treatment Advisory 1(1), 2001a.
  146. CSAT (Center for Substance Abuse Treatment). A Provider's Introduction to Substance Abuse Treatment for Lesbian, Gay, Bisexual, and Transgender Individuals. DHHS Publication No. (SMA) 01-3498. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2001b.
  147. CSAT (Center for Substance Abuse Treatment). Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004a.
  148. CSAT (Center for Substance Abuse Treatment). The Confidentiality of Alcohol and Drug Abuse Patient Records Regulation and the HIPAA Privacy Rule: Implications for Alcohol and Substance Abuse Programs. DHHS Publication No. (SMA) 04-3947. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004b. www​.hipaa.samhsa.gov​/download2/SAMHSAHIPAAComparisonClearedPDFVersion.pdf[accessed April 5, 2005].
  149. CSAT (Center for Substance Abuse Treatment). Substance Abuse Treatment and Family Therapy. Treatment Improvement Protocol (TIP) Series 39. DHHS Publication No. (SMA) 04-3957. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004c.
  150. CSAT (Center for Substance Abuse Treatment). Substance Abuse Treatment for Adults in the Criminal Justice System. Treatment Improvement Protocol (TIP) Series 44. DHHS Publication No. (SMA) 05-4056. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2005a.
  151. CSAT (Center for Substance Abuse Treatment). Substance Abuse Treatment for Persons With Co-Occurring Disorders. Treatment Improvement Protocol (TIP) Series 42. DHHS Publication No. (SMA) 05-3992. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2005b.
  152. CSAT (Center for Substance Abuse Treatment). Substance Abuse Treatment: Group Therapy. Treatment Improvement Protocol (TIP) Series 41. DHHS Publication No. (SMA) 05-3991. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2005c.
  153. CSAT (Center for Substance Abuse Treatment). Detoxification and Substance Abuse Treatment. Treatment Improvement Protocol (TIP) Series. Rockville, MD: Substance Abuse and Mental Health Services Administration, forthcominga.
  154. CSAT (Center for Substance Abuse Treatment). Improving Cultural Competence in Substance Abuse Treatment. Treatment Improvement Protocol (TIP) Series. Rockville, MD: Substance Abuse and Mental Health Services Administration, forthcomingb.
  155. CSAT (Center for Substance Abuse Treatment). Substance Abuse: Administrative Issues in Outpatient Treatment. Treatment Improvement Protocol (TIP) Series. Rockville, MD: Substance Abuse and Mental Health Services Administration, forthcomingc.
  156. CSAT (Center for Substance Abuse Treatment). Substance Abuse and Trauma. Treatment Improvement Protocol (TIP) Series. Rockville, MD: Substance Abuse and Mental Health Services Administration, forthcomingd.
  157. CSAT (Center for Substance Abuse Treatment). Substance Abuse: Clinical Issues in Intensive Outpatient Treatment. Treatment Improvement Protocol (TIP) Series. Rockville, MD: Substance Abuse and Mental Health Services Administration, forthcominge.
  158. CSAT (Center for Substance Abuse Treatment). Substance Abuse Treatment: Addressing the Specific Needs of Women. Treatment Improvement Protocol (TIP) Series. Rockville, MD: Substance Abuse and Mental Health Services Administration, forthcomingf.
  159. Czuchry M, Dansereau D F. A model of the effects of node-link mapping on drug abuse counseling. Addictive Behaviors. 2003;28(3):537–549. [PubMed: 12628625]
  160. Daley D. Dual disorders recovery counseling. In: Carroll, K.M., ed. Approaches to Drug Abuse Counseling. NIH Publication No. 00-4151. Rockville, MD: National Institute on Drug Abuse, 2000. 165.112.78.61/ADAC/ADAC3.html [accessed May 3, 2004].
  161. Daley D C. Relapse Prevention Workbook for Recovering Alcoholics and Drug-Dependent Persons, 3d ed. Holmes Beach, FL: Learning Publications, Inc., 2002.
  162. Dansereau D F, Joe G W, Dees S M, Simpson D D. Ethnicity and the effects of mapping-enhanced drug abuse counseling. Addictive Behaviors. 1996;21(3):363–376. [PubMed: 8883486]
  163. Darke S, Finlay-Jones R, Kaye S, Blatt T. Anti-social personality disorder and response to methadone maintenance treatment. Drug and Alcohol Review. 1996;15:271–276. [PubMed: 16203382]
  164. Darke S, Kaye S, Finlay-Jones R. Antisocial personality disorder, psychopathy and injecting heroin use. Drug and Alcohol Dependence. 1998;52(1):63–69. [PubMed: 9788008]
  165. Darke S, Ross J. The relationship between suicide and heroin overdose among methadone maintenance patients in Sydney, Australia. Addiction. 2001;96(10):1443–1453. [PubMed: 11571063]
  166. D'Aunno T, Pollack H A. Changes in methadone treatment practices: Results from a national panel study, 1988-2000. JAMA. 2002;288(7):850–856. [PubMed: 12186602]
  167. Dausey D J, Desai R A. Psychiatric comorbidity and the prevalence of HIV infection in a sample of patients in treatment for substance abuse. Journal of Nervous and Mental Disease. 2003;191(1):10–17. [PubMed: 12544594]
  168. Dawe S, Harnett P H, Staiger P, Dadds M R. Parent training skills and methadone maintenance: Clinical opportunities and challenges. Drug and Alcohol Dependence. 2000;60(1):1–11. [PubMed: 10821984]
  169. Dees S M, Dansereau D F, Simpson D D. Mapping-enhanced drug abuse counseling: Urinalysis results in the first year of methadone treatment. Journal of Substance Abuse Treatment. 1997;14(1):45–54. [PubMed: 9218236]
  170. De Leon G. Therapeutic communities. In: Galanter, M., and Kleber, H.D., eds. Textbook of Substance Abuse Treatment. Washington, DC: American Psychiatric Press, 1994, pp. 391–414.
  171. De Maria P. Methadone drug interactions. Journal of Maintenance in the Addictions. 2003;2(3):69–74.
  172. De Petrillo P B, Rice J M. Methadone dosing and pregnancy: Impact on program compliance. International Journal of the Addictions. 1995;30(2):207–217. [PubMed: 7759173]
  173. Di Clemente C C. Motivational interviewing and the stages of change. In: Miller, W.R., and Rollnick, S., eds. Motivational Interviewing: Preparing People To Change Addictive Behavior. New York: Guilford Press, 1991, pp. 191–202.
  174. Dinsmoor M J. Hepatitis C in pregnancy. Current Women's Health Reports. 2001;1(1):27–30. [PubMed: 12112948]
  175. Dodgen C, Shea W. Substance Abuse Disorders: Assessment and Treatment (Practical Resources for the Mental Health Professional). New York: Academic Press, 2000.
  176. Doherty M C, Garfein R S, Monterroso E M, Brown D, Vlahov D. Correlates of HIV infection among young adult short-term injection drug users. AIDS. 2000;14(6):717–726. [PubMed: 10807195]
  177. Dole V P. Addictive behavior. Scientific American. 1980;243(6):138–154. [PubMed: 7209482]
  178. Dole V P. Implications of methadone maintenance for theories of narcotic addiction. JAMA. 1988;260(20):3025–3029. [PubMed: 2846900]
  179. Dole V P, Kreek M J. Methadone plasma level: Sustained by a reservoir of drug in tissue. Proceedings of the National Academy of Sciences USA. 1973;70(1):10. [PMC free article: PMC433171] [PubMed: 4509643]
  180. Dole V P, Nyswander M E. Heroin addiction: A metabolic disease. Archives of Internal Medicine. 1967;120(1):19–24. [PubMed: 6028693]
  181. Doverty M, Somogyi A A, White J M, Bochner F, Beare C H, Menelaou A, Ling W. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain. 2001a;93(2):155–163. [PubMed: 11427327]
  182. Doverty M, White J M, Somogyi A A, Bochner F, Ali R, Ling W. Hyperalgesic responses in methadone maintenance patients. Pain. 2001b;90(12):91–96. [PubMed: 11166974]
  183. Drake, R E, Brunette M F. Complications of severe mental illness related to alcohol and drug use disorders. In: Galanter, M., ed. Recent Developments in Alcoholism, Volume 14: The Consequences of Alcoholism. New York: Plenum Press, 1998, pp. 285–299. [PubMed: 9751950]
  184. Drug Enforcement Administration, Office of Diversion Control. Narcotic Treatment Programs: Best Practice Guideline. Washington, DC: U.S. Department of Justice, 2000. www​.deadiversion.usdoj​.gov/pubs/manuals/narcotic/narcotic​.pdf[accessed May 3, 2004].
  185. Ducharme L J, Luckey J W. Implementation of the methadone treatment quality assurance system. Findings from the feasibility study. Evaluation & Health Professions. 2000;23(1):72–90. [PubMed: 10787952]
  186. Dupont R. Diagnostic testing—Laboratory and psychological. In: Gallanter, M., and Kleber, H.D., eds. Textbook of Substance Abuse Treatment, 2d ed. Washington, DC: American Psychiatric Press, 1999.
  187. Duvall H, Locke B, Brill L. Followup study of narcotic addicts five years after hospitalization. Public Health Reports. 1963;78:185–193. [PMC free article: PMC1915236] [PubMed: 19316439]
  188. Eap C B, Bertschy G, Powell K, Baumann P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. Journal of Clinical Psychopharmacology. 1997;17(2):113–117. [PubMed: 10950475]
  189. Eap C B, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clinical Pharmacokinetics. 2002;41(14):1153–1193. [PubMed: 12405865]
  190. Eap C B, Déglon J J, Baumann P. Pharmacokinetics and pharmacogenetics of methadone: Clinical relevance. Heroin Addiction and Related Problems. 1999;1(1):19–34.
  191. Edelin K C, Gurganious L, Golar K, Oellerich D, Kyei-Aboagye K, Adel Hamid M. Methadone maintenance in pregnancy: Consequences to care and outcome. Obstetrics and Gynecology. 1988;71(3):399–404. [PubMed: 3347426]
  192. Edlin B R, Seal K H, Lorvick J, Kral A H, Ciccarone D H, Moore L D, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? New England Journal of Medicine. 2001;345(3):211–215. [PMC free article: PMC1510901] [PubMed: 11463019]
  193. Edmunds M, Frank R, Hogan M, McCarty D, Robinson-Beale R, Weisner C eds. Managing Managed Care: Quality Improvement in Behavioral Health. Washington, DC: National Academy Press, 1997.
  194. El-Bassel N, Gilbert L, Rajah V, Foleno A, Frye V. Social support among women in methadone treatment who experience partner violence: Isolation and male controlling behavior. Violence Against Women. 2001;7(3):246–274.
  195. El-Bassel N, Gilbert L, Schilling R, Wada T. Drug abuse and partner violence among women in methadone treatment. Journal of Family Violence. 2000;15(3):209–228.
  196. El-Bassel N, Schilling R F, Turnbull J E, Su K H. Correlates of alcohol use among methadone patients. Alcohol Clinical Experimental Research. 1993;17(3):681–686. [PubMed: 8333601]
  197. Ellingstad T, Sobell L, Sobell M, Cleland P. Alcohol abusers who want to quit smoking: Implications for clinical treatment. Drug and Alcohol Dependence. 1999;54(3):259–265. [PubMed: 10372799]
  198. Epstein D, Preston K. Does cannabis use predict poor outcomes for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction. 2003;98(3):269–279. [PMC free article: PMC2943839] [PubMed: 12603227]
  199. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database of Systematic Reviews 2003(3):CD002208, 2003. [PubMed: 12917925]
  200. Fairbank J A, Dunteman G H, Condelli W S. Do methadone patients substitute other drugs for heroin? Predicting substance use at 1-year follow-up. American Journal of Drug and Alcohol Abuse. 1993;19(4):465–474. [PubMed: 8273767]
  201. Fallon B M. The Key Extended Entry Program (KEEP): From the community side of the bridge. Mount Sinai Journal of Medicine. 2001;68(1):21–27. [PubMed: 11135502]
  202. Fals-Stewart W, O'Farrell T J. Behavioral family counseling and naltrexone for male opioid-dependent patients. Journal of Consulting and Clinical Psychology. 2003;71(3):432–442. [PubMed: 12795568]
  203. Ferrando S J, Wall T L, Batki S L, Sorensen J L. Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. American Journal of Drug and Alcohol Abuse. 1996;22(4):475–487. [PubMed: 8911586]
  204. Fiellin D A, O'Connor P G. Office-based treatment of opioid-dependent patients. New England Journal of Medicine. 2002;347(11):817–823. [PubMed: 12226153]
  205. Fiellin D A, O'Connor P, Chawarski M, Pakes J P, Pantalon M V, Schottenfeld R S. Methadone maintenance in primary care: A randomized controlled trial. JAMA. 2001;286(14):1724–1731. [PubMed: 11594897]
  206. Finn P, Wilcock K. Levo-alpha acetyl methadol (LAAM): Its advantages and drawbacks. Journal of Substance Abuse Treatment. 1997;14(6):559–564. [PubMed: 9437627]
  207. Finnegan L P. ed. Drug Dependence in Pregnancy: Clinical Management of Mother and Child. National Institute on Drug Abuse. DHEW Publication No. (ADM) 79-678. Washington, DC: U.S. Govt. Print. Off., 1979.
  208. Finnegan L P. Treatment issues for opioid-dependent women during the perinatal period. Journal of Psychoactive Drugs. 1991;23(2):191–201. [PubMed: 1765892]
  209. Finnegan L P, Kaltenbach K. Neonatal abstinence syndrome. In: Hoekelman, R.A., and Nelson, N.M., eds. Primary Pediatric Care, 2d ed. St. Louis, MO: Mosby-Yearbook Publishers, 1992, pp. 1367–1378.
  210. Finnegan L P, Kandall S R. Maternal and neonatal effects of alcohol and drugs. In: Lowinson, J.H.; Ruiz, P.; and Millman, R.B., eds. Substance Abuse: A Comprehensive Textbook, 2d ed. Baltimore: Williams & Wilkins, 1992, pp. 628–656.
  211. Fischer G, Johnson R E, Eder H, Jagsch R, Peternell A, Wehinger M, Langer M, Aschauer H N. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction. 2000;95(2):239–244. [PubMed: 10723852]
  212. Flynn P M, Joe G W, Broome K M, Simpson D D, Brown B S. Recovery from opioid addiction in DATOS. Journal of Substance Abuse Treatment. 2003;25(3):177–186. [PubMed: 14670523]
  213. Folstein M F, Folstein S E, McHugh P R. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12(3):189–198. [PubMed: 1202204]
  214. Fontaine H, Chaix M L, Lagneau J L, Brechot C, Pol S. Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa [letter] Lancet. 2000;356:41. [PubMed: 10892765]
  215. Food and Drug Administration (FDA). FDA announces labeling changes following cardiac adverse events with addiction drug. FDA Talk Paper T01–15, April 20, 2001. Washington, DC: FDA, 2001. www​.fda.gov/bbs/topics​/ANSWERS/2001/ANS01076.html[accessed May 3, 2004].
  216. Forman R F, Bovasso G, Woody G. Staff beliefs about addiction treatment. Journal of Substance Abuse Treatment. 2001;21(1):1–9. [PubMed: 11516921]
  217. Frank B. An overview of heroin trends in New York City: Past, present, and future. Mount Sinai Journal of Medicine. 2000;67(56):340–346. [PubMed: 11064484]
  218. Frosch D L, Shoptaw S, Nahom D, Jarvik M E. Associations between tobacco smoking and illicit drug use among methadone-maintained opiate-dependent individuals. Experimental and Clinical Psychopharmacology. 2000;8(1):97–103. [PubMed: 10743909]
  219. Fudala P J, Bridge T P, Herbert S, Williford W O, Chiang C N, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith R J, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine. 2003;349(10):949–958. [PubMed: 12954743]
  220. Fuller C, Vlahov D, Arria A M, Ompad D, Garfein R, Strathdee S A. Factors associated with adolescent initiation of drug use. Public Health Report. 2001;116(Suppl. 1):136–145. [PMC free article: PMC1913680] [PubMed: 11889281]
  221. Fuller C M, Vlahov D, Ompad D C, Shah N, Arria A, Strathdee S A. High-risk behaviors associated with transition from illicit non-injection drug use among adolescent and young adult drug users: A case-control study. Drug and Alcohol Dependence. 2002;66:189–198. [PubMed: 11906806]
  222. Fuller R K, Hiller-Sturmhofel S. Alcoholism treatment in the United States: An overview. Alcohol Research and Health. 1999;23(2):69–77. [PubMed: 10890799]
  223. Fullilove R E, Fullilove M F, Bowser B P, Gross S A. Risk of sexually transmitted disease among black adolescent crack users in Oakland and San Francisco, California. JAMA. 1990;263:851–855. [PubMed: 2296147]
  224. Galen L W, Brower K J, Gillespie B W, Zucker R A. Sociopathy, gender, and treatment outcome among outpatient substance abusers. Drug and Alcohol Dependence. 2000;61(1):23–33. [PubMed: 11064181]
  225. Gearing F R, Schweitzer M D. An epidemiologic evaluation of long-term methadone maintenance treatment for heroin addiction. American Journal of Epidemiology. 1974;100:101–112. [PubMed: 4850534]
  226. Genevie L, Struening E L, Kallos J E, Geiler I, Muhlin G L, Kaplan S. Urban community reaction to health facilities in residential areas: Lessons from the placement of methadone facilities in New York City. International Journal of the Addictions. 1988;23(6):603–616. [PubMed: 3170049]
  227. George S, Braithwaite R A. A pilot study to determine the usefulness of the urinary excretion of methadone and its primary metabolite (EDDP) as potential markers of compliance in methadone detoxification programs. Journal of Analytical Toxicology. 1999;23(2):81–85. [PubMed: 10192409]
  228. George S, Braithwaite R A. Use of on-site testing for drugs of abuse. Clinical Chemistry. 2002;48(10):1639–1646. [PubMed: 12324478]
  229. George T P, Chawarski M C, Pakes J, Carroll K M, Kosten T R, Schottenfeld R S. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: A preliminary trial. Biological Psychiatry. 2000;47(12):1080–1086. [PubMed: 10862808]
  230. Geraghty B, Graham E A, Logan B, Weiss E L. Methadone levels in breast milk. Journal of Human Lactation. 1997;13(3):227–230. [PubMed: 9341416]
  231. Gerber J G, Rhodes R J, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2004;16(1):36–44. [PubMed: 14628297]
  232. Gerstein D R, Johnson R A, Foote M, Suter N, Jack K, Merker G, Turner S, Bailey R, Malloy K M, Williams E, Harwood H J. Evaluating Recovery Services: The California Drug and Alcohol Treatment Assessment (CALDATA): General Report. Sacramento, CA: California Department of Alcohol and Drug Programs, 1994.
  233. Gewirtz P D. Notes and comments: Methadone maintenance for heroin addicts. Yale Law Journal. 1969;78(7):1175–1211.
  234. Gilson S F, Chilcoat H D, Stapleton J M. Illicit drug use by persons with disabilities: Insights from the National Household Survey on Drug Abuse. American Journal of Public Health. 1996;86(11):1613–1615. [PMC free article: PMC1380698] [PubMed: 8916529]
  235. Glanz M, Klawansky S, McAullife W, Chalmers T. Methadone vs. L-alpha-acetylmethadol (LAAM) in the treatment of opiate addiction: A meta-analysis of the randomized, controlled trials. American Journal on Addictions. 1997;6(4):339–349. [PubMed: 9398932]
  236. Gleghorn A A.“Substance Abuse Policy: The San Francisco Perspective.” Presentation to the Little Hoover Commission, April 25, 2002. www​.lhc.ca.gov/lhcdir​/drug/GleghornApr25.pdf[accessed May 3, 2004].
  237. Glezen L A, Lowery C A. Practical issues of program organization and operation. In: Strain, E.C., and Stitzer, M.L., eds. Methadone Treatment for Opioid Dependence. Baltimore: Johns Hopkins University Press, 1999, pp. 223–250.
  238. Gourevitch M N, Friedland G H. Interactions between methadone and medications used to treat HIV infection: A review. Mount Sinai Journal of Medicine. 2000;67(56):429–436. [PubMed: 11064494]
  239. Gourevitch M N, Hartel D, Selwyn P A, Schoenbaum E E, Klein R S. Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. AIDS. 1999;13:2069–2074. [PubMed: 10546859]
  240. Gourevitch M N, Wasserman W, Panero M S, Selwyn P A. Successful adherence to observed prophylaxis and treatment among drug users in a methadone program. Journal of Addictive Diseases. 1996;15:93–104. [PubMed: 8729149]
  241. Graham A W, Schultz T K, Mayo-Smith M F, Ries R K, Wilford B B. Principles of Addiction Medicine, 3d ed. Chevy Chase, MD: American Society of Addiction Medicine, 2003.
  242. Greenfield L, Brady J V, Besteman K J, De Smet A. Patient retention in mobile and fixed-site methadone maintenance treatment. Drug and Alcohol Dependence. 1996;42:125–131. [PubMed: 8889411]
  243. Grella C E, Wugalter S E. Predictors of treatment retention in enhanced and standard methadone maintenance treatment for HIV risk reduction. Journal of Drug Issues. 1997;27(2):203–224.
  244. Griffith J D, Rowan-Szal G A, Roark R R, Simpson D D. Contingency management in outpatient methadone treatment: A meta-analysis. Drug and Alcohol Dependence. 2000;58(12):55–66. [PubMed: 10669055]
  245. Gruber K, Chutuape M A, Stitzer M L. Reinforcement-based intensive outpatient treatment for inner city opiate abusers: A short-term evaluation. Drug and Alcohol Dependence. 2000;57(3):211–223. [PubMed: 10661672]
  246. Haehl M. Important Prescribing Information for Addiction Treatment Specialists [letter, Dear Healthcare Professional]. Columbus, OH: Roxane Laboratories, Inc./Boehringer-Ingelheirn Pharmaceuticals, Inc., April 11, 2001.
  247. Hagopian G S, Wolfe H M, Sokol R J, Ager J W, Wardell J N, Cepeda E E. Neonatal outcome following methadone exposure in utero. Journal of Maternal-Fetal Medicine. 1996;5(6):348–354. [PubMed: 8972413]
  248. Hall R C W, Platt D E, Hall R C W. Suicide risk assessment: A review of risk factors for suicide in 100 patients who made severe suicide attempts: Evaluation of suicide risk in a time of managed care. Psychosomatics. 1999;40(1):18–27. [PubMed: 9989117]
  249. Hall W D, Wodak A. Is naltrexone a cure for heroin dependence? Medical Journal of Australia. 1999;171(1):26–30. [PubMed: 10451663]
  250. Hamilton S P, Nunes E V, Janal M, Weber L. The effect of sertraline on methadone plasma levels in methadone-maintenance patients. American Journal on Addictions. 2000;9(1):63–69. [PubMed: 10914294]
  251. Hammack L. Methadone: Culprit or cure? Roanoke Times and World News, August 11, 2002, p. A1.
  252. Hardman J G, Limbird L E, Goodman-Gilman A eds. Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 10th ed. New York: McGraw-Hill, 2001.
  253. Hardman J G, Limbird L E, Molinoff P B, Ruddon R W, Gilman A G, eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill, 1996.
  254. Harper R G, Solish G, Feingold E, Gersten-Woolf N B, Sokal M M. Maternal ingested methadone, body fluid methadone, and the neonatal withdrawal syndrome. American Journal of Obstetrics and Gynecology. 1977;129(4):417–424. [PubMed: 910821]
  255. Hartel D M, Schoenbaum E E. Methadone treatment protects against HIV infection: Two decades of experience in the Bronx, New York City. Public Health Reports. 1998;113(Suppl. 1):107–115. [PMC free article: PMC1307733] [PubMed: 9722816]
  256. Hawkins J D, Catalano R F, Miller J Y. Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: Implications for substance abuse prevention. Psychological Bulletin. 1992;112:64–105. [PubMed: 1529040]
  257. Hawks R L. Analysis methodology. In: Hawks, R.L., and Chiang, C.N., eds. Urine Testing for Drugs of Abuse. NIDA Research Monograph 73. Washington, DC: Supt. of Docs., U.S. Govt. Print. Off., 1986, pp. 30–42.
  258. Hellewell J S. Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: A review of efficacy and tolerability. Journal of Affective Disorders. 2002;72(Suppl. 1):S23–S34. [PubMed: 12589900]
  259. Herman M, Gourevitch M N. Integrating primary care and methadone maintenance treatment:Implementation issues. Journal of Addictive Diseases. 1997;16(1):91–102. [PubMed: 9046446]
  260. Hien D A, Nunes E, Levein F R, Fraser D. Posttraumatic stress disorder and short-term outcome in early methadone treatment. Journal of Substance Abuse Treatment. 2000;19:31–37. [PubMed: 10867298]
  261. Higgins E S. A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder. Journal of Family Practice. 1999;48(1):15–20. [PubMed: 9934377]
  262. Higgins S T, Abbott P J. CRA and treatment of cocaine and opioid dependence. In: Meyers, R.J., and Miller, W.R., eds. A Community Reinforcement Approach to Addiction Treatment. Cambridge, UK: Cambridge University Press, 2001, pp. 123–146.
  263. Ho V. Methadone hits road to help area's addicts. Seattle Post-Intelligencer Reporter, October 14, 1999. seattlepi.nwsource.com/local/meth14.shtml [accessed May 3, 2004].
  264. Hoegerman G, Wilson C, Thurmond E, Schnoll S. Drug-exposed neonates. Western Journal of Medicine. 1990;152:559–564. [PMC free article: PMC1002411] [PubMed: 2190424]
  265. Hoffman J A, Moolchan E T. The phases-of-treatment model for methadone maintenance: Implementation and evaluation. Journal of Psychoactive Drugs. 1994;26(2):181–197. [PubMed: 7931863]
  266. Howard K, Bell J, Christie M J. Measuring heroin use in methadone programmes. Drug and Alcohol Review. 1995;14:27–34. [PubMed: 16203293]
  267. Hubbard R L, Craddock S G, Anderson J. Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). Journal of Substance Abuse Treatment. 2003;25(3):125–134. [PubMed: 14670518]
  268. Hubbard R L, Craddock S G, Flynn P M, Anderson J, Etheridge R M. Overview of 1-year follow-up outcomes in drug abuse treatment outcome study (DATOS). Psychology of Addictive Behavior. 1997;11(4):261–278.
  269. Hubbard R L, Rachal, J V, Harwood H J. Drug Abuse Treatment: A National Study of Effectiveness. Chapel Hill, NC: University of North Carolina Press, 1989.
  270. Hubble M, Duncan B, Miller S. The Heart and Soul of Change. Washington, DC: American Psychological Association, 1999.
  271. Hughes J R. Combining behavioral therapy and pharmacotherapy for smoking cessation: An update. In: Onken, L.S.; Blaine, J.D.; and Boren, J.J., eds. Integrating Behavioral Therapies With Medications in the Treatment of Drug Dependence. NIDA Research Monograph 150. DHHS Publication No. (NIH) 95-3899. Rockville, MD: National Institute on Drug Abuse, 1995, pp. 92–109.
  272. Hughes T L, Eliason M. Substance abuse in lesbian, gay, bisexual, and transgender populations. Journal of Primary Prevention. 2002;22(3):263–298.
  273. Hunt G, Rosenbaum M.“Hustling” within the clinic: Consumer perspectives on methadone maintenance treatment. In: Inciardi, J.A., and Harrison, L.D., eds. Heroin in the Age of Crack Cocaine. Thousand Oaks, CA: Sage Publications, Inc., 1998, pp. 188–214.
  274. Hunt G H, Odoroff M E. Followup study of narcotic drug addicts after hospitalization. Public Health Reports. 1962;77(1):41–54. [PMC free article: PMC1914646] [PubMed: 14450025]
  275. Iguchi M Y, Belding M A, Morral A R, Lamb R J, Husband S D. Reinforcing operants other than abstinence in drug abuse treatment: An effective alternative for reducing drug use. Journal of Consulting and Clinical Psychology. 1997;65(3):421–428. [PubMed: 9170765]
  276. Iguchi M Y, Lamb R J, Belding M A, Platt J J, Husband S D, Morral A R. Contingent reinforcement of group participation versus abstinence in a methadone maintenance program. Experimental & Clinical Psychopharmacology. 1996;4(3):315–321.
  277. Inciardi J A. Some considerations on the clinical efficacy of compulsory treatment: Reviewing the New York experience. In: Leukefeld, C.G., and Tims, F.M., eds. Compulsory Treatment of Drug Abuse: Research and Clinical Practice. NIDA Research Monograph 86. NIH Publication No. 94-3713. Rockville, MD: National Institute on Drug Abuse, 1988, reprinted 1994, pp. 126–138. [PubMed: 2845272]
  278. Inglesby T V, Rai R, Astemborski J, Gruskin L, Nelson K E, Vlahov D, Thomas D L. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology. 1999;29(2):590–596. [PubMed: 9918940]
  279. Institute of Medicine. Federal Regulation of Methadone Treatment. Washington, DC: National Academy Press, 1995.
  280. Inturrisi C E, Verebely K. The levels of methadone in the plasma in methadone maintenance. Clinical Pharmacology and Therapeutics. 1972;13:633–637. [PubMed: 5053808]
  281. Jamison R N, Kauffman J, Katz N P. Characteristics of methadone maintenance patients with chronic pain. Journal of Pain and Symptom Management. 2000;19(1):53–62. [PubMed: 10687327]
  282. Jarvis M A, Schnoll S H. Methadone use during pregnancy. In: Chiang, C.N., and Finnegan, L.P., eds. Medication Development for the Treatment of Pregnant Addicts and Their Infants. NIDA Research Monograph 149. NIH Publication No. 95-3891. Rockville, MD: National Institute on Drug Abuse, 1995, pp. 58–77.
  283. Jarvis M A, Wu-Pong S, Kniseley J S, Schnoll S H. Alterations in methadone metabolism during late pregnancy. Journal of Addictive Diseases. 1999;18(4):51–61. [PubMed: 10631963]
  284. Jensen T, Jacobsen D, von der Lippe E, Heier M S, Selseth B. [Clinical botulism among injecting drug users] Tidsskrift Nor Laegeforen. 1998;118(28):4363–4365. [PubMed: 9889608]
  285. Jeremy R J, Hans S L. Behavior of neonates exposed in utero to methadone as assessed on the Brazelton Scale. Infant Behavior and Development. 1985;8:323–336.
  286. Joe G W, Brown B S, Simpson D. Psychological problems and client engagement in methadone treatment. Journal of Nervous and Mental Disease. 1995;183(11):704–710. [PubMed: 7595433]
  287. Joe G W, Simpson D D, Broome K M. Effects of readiness for drug abuse treatment on client retention and assessment of process. Addiction. 1998;93(8):1177–1190. [PubMed: 9813899]
  288. Joe G W, Simpson D D, Dansereau D F, Rowan-Szal G A. Relationships between counseling rapport and drug abuse treatment outcomes. Psychiatric Services. 2001;52(9):1223–1229. [PubMed: 11533397]
  289. Johnson H L, Glasman M B, Fiks K B, Rosen T S. Path analysis of variables affecting 36-month outcome in a population of multi-risk children. Infant Behavior and Development. 1987;10:451–465.
  290. Johnson R E, Chutuape M A, Strain E C, Walsh S L, Stitzer M L, Bigelow G E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medicine. 2000;343(18):1290–1297. [PubMed: 11058673]
  291. Johnson R E, Jones H E, Fischer G. Use of buprenorphine in pregnancy: Patient management and effects on the neonate. Drug and Alcohol Dependence. 2003a;70(Suppl. 2):S87–S101. [PubMed: 12738353]
  292. Johnson R E, Jones H E, Jasinski D R, Svikis D S, Haug N A, Jansson L M, Kissin W B, Alpan G, Lantz M E, Cone E J, Wilkins D G, Golden A S, Huggins G R, Lester B M. Buprenorphine treatment of pregnant opioid-dependent women: Maternal and neonatal outcomes. Drug and Alcohol Dependence. 2001;63:97–103. [PubMed: 11297835]
  293. Johnson R E, Strain E C. Other medications for opioid dependence. In: Strain, E.C., and Stitzer, M.L., eds. Methadone Treatment for Opioid Dependence. Baltimore: Johns Hopkins University Press, 1999, pp. 281–321.
  294. Johnson R E, Strain E C, Amass L. Buprenorphine: How to use it right. Drug and Alcohol Dependence. 2003b;70(Suppl.):S59–S77. [PubMed: 12738351]
  295. Jones H E, Haug N, Silverman K, Stitzer M, Svikis D. The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. Drug and Alcohol Dependence. 2001;61:297–306. [PubMed: 11164694]
  296. Jones H E, Haug N A, Stitzer M L, Svikis D S. Improving treatment outcomes for pregnant drug-dependent women using low-magnitude voucher incentives. Addictive Behaviors. 2000;25(2):263–267. [PubMed: 10795950]
  297. Jones S S, Power D, Dale A. The patients' charter: Drug users' views on the “ideal” methadone programme. Addiction Research. 1994;1(4):323–334.
  298. Joseph H. The criminal justice system and opiate addiction: A historical perspective. In: Leukefeld, C.G., and Tims, F.M., eds. Compulsory Treatment of Drug Abuse: Research and Clinical Practice. NIDA Research Monograph 86. NIH Publication No. 94-3713. Rockville, MD: National Institute on Drug Abuse, 1988, reprinted 1994, pp. 106–125.
  299. Joseph H, Dole V P. Methadone patients on probation and parole. Federal Probation June 1970, pp. 42–48.
  300. Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): A review of historical and clinical issues. Mount Sinai Journal of Medicine. 2000;67(56):347–364. [PubMed: 11064485]
  301. Juliana P, Goodman, C. Children of substance abusing parents. In: Lowinson, J.H.; Ruiz, P.; Millman, R.B.; and Langrod, J.G., eds. Substance Abuse: A Comprehensive Textbook, 3d ed. Baltimore: Williams & Wilkins, 1997, pp. 665–671.
  302. Kachur S P, DiGuiseppi C. Screening for suicide risk. In: Guide to Clinical Preventive Services, 2d ed. Washington, DC: Office of Disease Prevention and Health Promotion, U.S. Department of Health and Human Services, 1996. cpmcnet.columbia.edu/texts/gcps/gcps0060.html [accessed May 3, 2004].
  303. Kadden R, Carroll K, Donovan D, Cooney N, Monti P, Abrams D, Litt M, Hester R eds. Cognitive-Behavioral Coping Skills Therapy Manual. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism, 1992.
  304. Kakko J, Svanborg K D, Kreek M J, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. Lancet. 2003;361:662–668. [PubMed: 12606177]
  305. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstetrics and Gynecology Clinics of North America. 1998;25(1):139–151. [PubMed: 9547764]
  306. Kaltenbach, K, Comfort, M L. Methadone maintenance of greater than 80 mg during pregnancy. In: Harris, L.S., ed. Problems of Drug Dependence 1996: Proceedings of the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence. NIDA Research Monograph 174. NIH Publication No. 97-4236. Rockville, MD: National Institute on Drug Abuse, 1997, p. 128.
  307. Kaltenbach K, Finnegan L P. Developmental outcome of infants exposed to methadone in utero: A longitudinal study. Pediatric Research. 1986;20:57.
  308. Kaltenbach K, Finnegan L P. Perinatal and developmental outcome of infants exposed to methadone in utero. Neurotoxicology and Teratology. 1987;9:311–313. [PubMed: 3683349]
  309. Kaltenbach K, Silverman N, Wapner R. Methadone maintenance during pregnancy. In: State Methadone Treatment Guidelines. Treatment Improvement Protocol (TIP) Series 1. DHHS Publication No. (SMA) 02-3624. Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 1993, reprinted 2000, 2002.
  310. Kanchana T P, Kaul V, Manzarbeitia C, Reich D J, Hails K C, Munoz S J, Rothstein K D. Liver transplantation for patients on methadone maintenance. Liver Transplantation. 2002;8(9):778–782. [PubMed: 12200777]
  311. Kandall S R, Albin R S, Gartner L M, Lee K S, Eidelman A, Lowinson J. The narcotic dependent mother: Fetal and neonatal consequences. Early Human Development. 1977;1:159–169. [PubMed: 617308]
  312. Kandall S R, Doberczak T M, Jantunen M, Stein J. The methadone-maintained pregnancy. Clinics in Perinatology. 1999;26(1):173–183. [PubMed: 10214548]
  313. Kang S Y, Magura S, Nwakeze P, Demsky S. Counselor attitudes in methadone maintenance. Journal of Maintenance in the Addictions. 1997;1(2):41–58.
  314. Katz N, Fanciullo G J. Role of urine toxicology testing in the management of chronic opioid therapy. Clinical Journal of Pain. 2002;18(Suppl. 4):S76–S82. [PubMed: 12479257]
  315. Kehoe K A, Melkus G D, Newlin K. Culture within the context of care: An integrative review. Ethnicity and Disease. 2003;13(3):344–353. [PubMed: 12894959]
  316. Kessler R C. Epidemiology of psychiatric comorbidity. In: Tsuang, M.T.; Tohen, M.; and Zahner, G.E.P., eds. Textbook of Psychiatric Epidemiology. New York: John Wiley & Sons, 1995, pp. 179–197.
  317. Kessler R C, McGonagle K A, Zhao S, Nelson C B, Hughes M, Eshleman S, Wittchen H U, Kendler K S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Study. Archives of General Psychiatry. 1994;51:8–19. [PubMed: 8279933]
  318. Kessler R C, Nelson C B, McGonagle K A, Edlund M J, Frank R G, Leaf P J. The epidemiology of co-occurring addictive and mental disorders: Implications for prevention and service utilization. American Journal of Orthopsychiatry. 1996;66(1):17–31. [PubMed: 8720638]
  319. Khantzian E J. The self-medication hypothesis of addictive disorders: Focus on heroin and cocaine dependence. American Journal of Psychiatry. 1985;142(11):1259–1264. [PubMed: 3904487]
  320. Kidorf M, Brooner R K, King V L. Motivating methadone patients to include drug-free significant others in treatment: A behavioral intervention. Journal of Substance Abuse Treatment. 1997;14(1):23–28. [PubMed: 9218233]
  321. Kidorf M, Hollander J R, King V L, Brooner R K. Increasing employment of opioid dependent outpatients: An intensive behavioral intervention. Drug and Alcohol Dependence. 1998;50(1):73–80. [PubMed: 9589274]
  322. Kidorf M, King V L, Brooner R K. Integrating psychosocial services with methadone treatment. In: Strain, E.C., and Stitzer, M.L., eds. Methadone Treatment for Opioid Dependence. Baltimore: Johns Hopkins University Press, 1999, pp. 166–195.
  323. Kidwell D A, Lee E H, DeLauder S F. Evidence for bias in hair testing and procedures to correct bias. Forensic Science International. 2000;107(13):39–61. [PubMed: 10689561]
  324. King V L, Brooner R K, Kidorf M S, Stoller K B, Mirsky A F. Attention deficit hyperactivity disorder and treatment outcome in opioid abusers entering treatment. Journal of Nervous and Mental Disease. 1999;187(8):487–495. [PubMed: 10463066]
  325. King V L, Kidorf M S, Stoller K B, Brooner R K. Influence of psychiatric comorbidity on HIV risk behaviors: Changes during drug abuse treatment. Journal of Addictive Diseases. 2000;19(4):65–83. [PubMed: 11110066]
  326. King V L, Kidorf M S, Stoller K B, Carter J A, Brooner R K. Influence of antisocial personality subtypes on drug abuse treatment response. Journal of Nervous and Mental Disease. 2001;189(9):593–601. [PubMed: 11580002]
  327. King V L, Stoller K B, Hayes M, Umbricht A, Currens M, Kidorf M S, Carter J A, Schwartz R, Brooner R K. A multicenter randomized evaluation of methadone medical maintenance. Drug and Alcohol Dependence. 2002;65(2):137–148. [PubMed: 11772475]
  328. Kintz P. Deaths involving buprenorphine: A compendium of French cases. Forensic Science International. 2001;121:65–69. [PubMed: 11516889]
  329. Kintz P. Buprenorphine-related deaths. In: Kintz, P., and Marquet, P., eds. Forensic Science and Medicine: Buprenorphine Therapy of Opiate Addiction. Totowa, NJ: Humana Press, 2002, pp. 109–117.
  330. Kintz P, Samyn N. Use of alternative specimens: Drugs of abuse in saliva and doping agents in hair. Therapeutic Drug Monitoring. 2002;24(2):239–246. [PubMed: 11897970]
  331. Kipnis S S, Herron A, Perez J, Joseph H. Integrating the methadone patient in the traditional addiction inpatient rehabilitation program: Problems and solutions. Mount Sinai Journal of Medicine. 2001;68(1):28–32. [PubMed: 11135503]
  332. Kleber H D. Concomitant use of methadone with other psychoactive drugs in the treatment of opiate addicts with other DSM-III diagnoses. In: Cooper, J.R.; Altman, F.; Brown, B.S.; and Czechowicz, D., eds. Research on the Treatment of Narcotic Addiction: State of the Art. NIDA Treatment Research Monograph Series. DHHS Publication No. (ADM) 83-1281. Washington, DC: Supt. of Docs., U.S. Govt. Print. Off., 1983, pp. 119–148.
  333. Kleber H D, Kosten T R, Gaspari J, Topazian M. Nontolerance to opioid antagonism of naltrexone. Biological Psychiatry. 1985;20(1):66–72. [PubMed: 2981129]
  334. Knight K R, Rosenbaum M, Irwin J, Kelley M S, Wenger L, Washburn A. Involuntary versus voluntary detoxification from methadone maintenance treatment: The importance of choice. Addiction Research. 1996a;3(4):351–362.
  335. Knight K R, Rosenbaum M, Kelley M S, Irwin J, Washburn A, Wenger L. Defunding the poor: The impact of lost access to subsidized methadone maintenance treatment on women injection drug users. Journal of Drug Issues. 1996b;26(4):923–942.
  336. Kobayashi K, Yamamoto T, Chiba K, Tani M, Shimada N, Ishizaki T, Kuroiwa Y. Human buprenorphine N-dealkylation is catabolized by cytochrome P4503A4. Drug Metabolism and Disposition. 1998;26(8):818–821. [PubMed: 9698298]
  337. Koch M, Banys P. Liver transplantation and opioid dependence. JAMA. 2001;285(8):1056–1058. [PubMed: 11209177]
  338. Koch M, Banys P. Methadone is a medication, not an addiction. Liver Transplantation. 2002;8(9):783–786. [PubMed: 12200778]
  339. Koester S, Anderson K, Hoffer L. Active heroin injectors' perceptions and use of methadone maintenance treatment: Cynical performance or self-prescribed risk reduction? Substance Use & Misuse. 1999;34(14):2135–2153. [PubMed: 10573308]
  340. Kosten T R. Client issues in drug abuse treatment: Addressing multiple drug abuse. In: Pickens, R.W.; Leukefeld, C.G.; and Schuster, C.R., eds. Improving Drug Abuse Treatment. NIDA Research Monograph 106. DHHS Publication No. (ADM) 91-1754. Washington, DC: Supt. of Docs., U.S. Govt. Print. Off., 1991, pp. 136–151.
  341. Kosten T R, Rounsaville B J. Suicidality among opioid addicts: 2.5 year follow-up. American Journal of Drug and Alcohol Abuse. 1988;14(3):357–369. [PubMed: 3189257]
  342. Krambeer L L, von McKnelly W Jr, Gabrielli W F Jr, Penick E C. Methadone therapy for opioid dependence. American Family Physician. 2001;63(12):2404–2410. [PubMed: 11430455]
  343. Krantz M J, Kutinsky I B, Robertson A D, Mehler P S. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy. 2003;23(6):802–805. [PubMed: 12820821]
  344. Krantz M J, Mehler P S. Treating opioid dependence: Growing implications for primary care. Archives of Internal Medicine. 2004;164(3):277–288. [PubMed: 14769623]
  345. Krausz M, Degkwitz P, Haasen C, Verthein U. Opioid addiction and suicidality. Crisis. 1996;17(4):175–181. [PubMed: 9018906]
  346. Kreek M J. Plasma and urine levels of methadone. New York State Journal of Medicine. 1973;73(23):2773–2777. [PubMed: 4520357]
  347. Kreek M J. Opiate-ethanol interactions: Implications for the biological basis and treatment of combined addictive diseases. In: Harris, L.S., ed. Problems of Drug Dependence, 1987: Proceedings of the 49th Annual Scientific Meeting of the Committee on Problems of Drug Dependence, Inc. NIDA Research Monograph 81. DHHS Publication No. (ADM) 88-1564. Rockville, MD: National Institute on Drug Abuse, 1987.
  348. Kwiatkowski C F, Booth R E, Lloyd L V. The effects of offering free treatment to street-recruited opioid injectors. Addiction. 2000;95(5):697–704. [PubMed: 10885044]
  349. Labbate L A. Paruresis and urine drug testing. Depression and Anxiety. 1997;4(5):249–252. [PubMed: 9167794]
  350. Lacroix I, Berrebi A, Chaumerliac C, Lapeyre-Mestre M, Montastruc J L, Damase-Michel C. Buprenorphine in pregnant opioid-dependent women: First results of a prospective study. Addiction. 2004;99(2):209–214. [PubMed: 14756713]
  351. Landry M J. Overview of Addiction Treatment Effectiveness. Rockville, MD: Office of Applied Studies, Substance Abuse and Mental Health Services Administration, 1997.
  352. Lau D T Y, Kleiner D E, Ghany M G, Park Y, Schmid P, Hoofnagle J H. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology. 1998;28(4):1121–1127. [PubMed: 9755252]
  353. Lawmakers may restrict methadone clinic sites. Bergen Record, December 27, 2000, p. A6.
  354. Lawson A W. Substance abuse problems of the elderly: Considerations for treatment and prevention. In: Lawson, G.W., and Lawson, A.W., eds. Alcohol and Substance Abuse in Special Populations. Rockville, MD: Aspen Publishers, 1989, pp. 95–113.
  355. Leavitt S B, Shinderman M, Maxwell S, Eap C B, Paris P. When “enough” is not enough: New perspectives on optimal methadone maintenance dose. Mount Sinai Journal of Medicine. 2000;67(56):404–411. [PubMed: 11064491]
  356. Lejeune C, Aubisson S, Simmat-Durand L, Cneude F, Piquet M, Gourarier L. Buprenorphine and pregnancy: A comparative, multicenter clinical study of high-dose buprenorphine versus methadone maintenance. In: Kintz, P., and Marquet, P., eds. Buprenorphine Therapy of Opiate Addiction. Totowa, NJ: Humana Press, 2002, pp. 137–146.
  357. Levin F R, Evans S M, Kleber H D. Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. Drug and Alcohol Dependence. 1998;52(1):15–25. [PubMed: 9788002]
  358. Levy R H, Thummel K E, Trager W F, Hansten P D, Eichelbaum M eds. Metabolic Drug Interactions. Philadelphia: Lippincott–Williams & Wilkins, 2000.
  359. Lewis D C. Access to narcotic addiction treatment and medical care: Prospects for the expansion of methadone maintenance treatment. Journal of Addictive Diseases. 1999;18(2):5–21. [PubMed: 10334372]
  360. Lifschitz M H, Wilson G S, Smith E O, Desmond M M. Fetal and postnatal growth of children born to narcotic-dependent women. Journal of Pediatrics. 1983;102:686–691. [PubMed: 6842322]
  361. Lifschitz M H, Wilson G S, Smith E O, Desmond M M. Factors affecting head growth and intellectual function in children of drug addicts. Pediatrics. 1985;75(2):269–274. [PubMed: 3969327]
  362. Lindesmith Center-Drug Policy Foundation. About Methadone. New York: Lindesmith Center-Drug Policy Foundation, 2000.
  363. Ling W, Charuvastra C, Collins J F, Batki S, Brown L S Jr, Kintaudi P, Wesson D R, McNicholas L, Tusel D J, Malkerneker V, Renner J A Jr, Santos E, Casadonte P, Fye C, Stine S, Wang R I, Segal D. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction. 1998;93(4):475–486. [PubMed: 9684386]
  364. Lisi A M, Kazlauskas R, Trout G J. Gas chromatographic-mass spectrometric quantitation of urinary buprenorphine and norbuprenorphine after derivatization by direct extractive alkylation. Journal of Chromatography B. 1997;692(1):67–77. [PubMed: 9187385]
  365. Lombardi E L, van Servellen G. Building culturally sensitive substance use prevention and treatment programs for transgendered populations. Journal of Substance Abuse Treatment. 2000;19:291–296. [PubMed: 11027900]
  366. Lowinson J H, Langrod J. Neighborhood drug treatment center; opposition to establishment: Problem in community medicine. New York State Journal of Medicine. 1975;75(5):766–769. [PubMed: 1054796]
  367. Luborsky L, Woody G E, Hole A V, Velleco A. Supportive-expressive dynamic psychotherapy of opiate drug dependence. In: Barber, J., and Crits-Christoph, P., eds. Therapies for Psychiatric Disorders (Axis I). New York: Basic Books, 1995.
  368. Lubrano S, Pacini M, Giuntoli G, Maremmani I. Is craving for heroin and alcohol related to low methadone dosages in methadone maintained patients? Heroin Addiction and Related Clinical Problems. 2002;4(2):11–18.
  369. Maany I, Dhopesh V, Arndt I O, Burke W, Woody G, O'Brien C P. Increase in desipramine serum levels associated with methadone treatment. American Journal of Psychiatry. 1989;146(12):1611–1613. [PubMed: 2486749]
  370. Madden J D, Chappel J N, Zuspan F, Gumpel J, Mejia A, Davis R. Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology. 1977;127:199–201. [PubMed: 831502]
  371. Magura S, Nwakeze P C, Demsky S. Pre- and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction. 1998;93(1):51–60. [PubMed: 9624711]
  372. Magura S, Nwakeze P C, Kang S Y, Demsky S. Program quality effects on patient outcomes during methadone maintenance: A study of 17 clinics. Substance Use & Misuse. 1999;34(9):1299–1324. [PubMed: 10419225]
  373. Magura S, Rosenblum A. Leaving methadone treatment: Lessons learned, lessons forgotten, lessons ignored. Mount Sinai Journal of Medicine. 2001;68(1):62–74. [PubMed: 11135508]
  374. Magura S, Rosenblum A, Fong C, Villano C, Richman B. Treating cocaine-using methadone patients: Predictors of outcomes in a psychosocial clinical trial. Substance Use & Misuse. 2002;37(14):1927–1955. [PubMed: 12511059]
  375. Magura S, Rosenblum A, Lewis C, Joseph H. The effectiveness of in-jail methadone maintenance. Journal of Drug Issues. 1993;23(1):75–99.
  376. Malpas T J, Darlow B A, Lennox R, Horwood L J. Maternal methadone dosage and neonatal withdrawal. Australian and New Zealand Journal of Obstetrics and Gynaecology. 1995;35(2):175–177. [PubMed: 7677682]
  377. Manno J E. Interpretation of urinalysis results. In: Hawks, R.L., and Chiang, C.N., eds. Urine Testing for Drugs of Abuse. NIDA Research Monograph 73. Washington, DC: Supt. of Docs., U.S. Govt. Print. Off., 1986, pp. 54–61.
  378. Manns M P, McHutchinson J G, Gordon S C, Rustgi V K, Shiffman M, Reindollar R, Goodman Z D, Koury K, Ling M, Albrecht J K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358(9286):958–965. [PubMed: 11583749]
  379. Margolis R D, Zweben J E. Treating Patients With Alcohol and Other Drug Problems: An Integrated Approach. Washington, DC: American Psychological Association, 1998.
  380. Mark T, Woody G E, Juday T, Kleber H D. The economic costs of heroin addiction in the United States. Drug and Alcohol Dependence. 2001;61:195–206. [PubMed: 11137285]
  381. Marlatt G A. Cognitive factors in the relapse process. In: Marlatt, G.A., and Gordon, J.R., eds. Relapse Prevention. New York: Guilford Press, 1985.
  382. Marlatt G A, Gordon J R. Determinants of relapse: Implications for the maintenance of behavior change. In: Davidson, P.O., and Davidson, S.M., eds. Behavioral Medicine: Changing Health Lifestyles. New York: Brunner/Mazel, 1980.
  383. Marlowe D B, Glass D J, Merikle E P, Festinger D S, DeMatteo D S, Marczyk G R, Platt J J. Efficacy of coercion in substance abuse treatment. In: Tims, F.M.; Leukefeld, C.G.; and Platt, J.J., eds. Relapse and Recovery in Addictions. New Haven, CT: Yale University Press, 2001, pp. 208–227.
  384. Marquet P, Chevrel J, Lavignasse P, Merle L, Lachâtre G. Buprenorphine withdrawal syndrome in a newborn. Clinical Pharmacology & Therapeutics. 1997;62(5):569–571. [PubMed: 9390114]
  385. Marquet P, Lavignasse P, Chevrel J, Lachâtre G, Merle L. In utero exposure to Subutex® induces no or mild withdrawal syndromes in the newborn. Therapie. 1998;53:178.
  386. Marray M. P450 enzymes: Inhibition mechanisms, genetic regulation and liver disease. Clinical Pharmacokinetics. 1992;23(2):132–146. [PubMed: 1511529]
  387. Martell B A, Arnsten J H, Ray B, Gourevitch M N. The impact of methadone induction on cardiac conduction in opiate users (letter to the editor). Annals of Internal Medicine. 2003;139(2):154–155. [PubMed: 12859171]
  388. Mason B J, Kocsis J H, Melia D, Khuri E T, Sweeney J, Wells A, Borg L, Millman R B, Kreek M J. Psychiatric comorbidity in methadone maintained patients. Journal of Addictive Diseases. 1998;17(3):75–89. [PubMed: 9789161]
  389. Mattick R P, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence (Cochrane Review). Cochrane Database Systems Review 2003(2):CD00209, 2003. [PubMed: 12804430]
  390. Maxwell S, Shinderman M S. Optimizing long-term response to methadone maintenance treatment: A 152-week follow-up using higher-dose methadone. Journal of Addictive Diseases. 2002;21(3):1–12. [PubMed: 12094996]
  391. Mayes L C, Carroll K M. Neonatal withdrawal syndrome in infants exposed to cocaine and methadone. Substance Use & Misuse. 1996;31(2):241–253. [PubMed: 8834011]
  392. McAuliffe W E. A randomized controlled trial of recovery training and self-help for opioid addicts in New England and Hong Kong. Journal of Psychoactive Drugs. 1990;22(2):197–209. [PubMed: 2197394]
  393. McCance-Katz E F, Farber S, Selwyn P A, O'Connor A. Decrease in methadone levels with nelfinavir mesylate. American Journal of Psychiatry. 2000;157(3):481. [PubMed: 10698844]
  394. McCann M J, Rawson R A, Obert J L, Hasson, A J. Treatment of Opiate Addiction With Methadone: A Counselor Manual. Technical Assistance Publication (TAP) Series 7. DHHS Publication No. (SMA) 00-3453. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1994, reprinted 1999, 2000.
  395. McCarthy J. Quantitative urine drug monitoring in methadone programs: Potential clinical uses. Journal of Psychoactive Drugs. 1994;26(2):199–206. [PubMed: 7931864]
  396. McCarthy J J, Posey B L. Methadone levels in human milk. Journal of Human Lactation. 2000;16(2):115–120. [PubMed: 11153342]
  397. McCoy A W. Historical Review of Opium/Heroin Production, n.d. www.druglibrary.org/ Schaffer/heroin/historic.htm[accessed May 3, 2004].
  398. McGarrity L. Wound botulism in injecting drug users [letter] Anaesthesia. 2002;57:284–313. [PubMed: 11892652]
  399. McKinnon K, Cournos F, Herman R. HIV among people with chronic mental illness. Psychiatric Quarterly. 2002;73(1):17–31. [PubMed: 11780595]
  400. McLellan A T, Arndt I O, Metzger D S, Woody G E, O'Brien C P. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269(15):1953–1959. [PubMed: 8385230]
  401. McLellan A T, Grissom G R, Zanis D, Randall M, Brill P, O'Brien C P. Problem-service “matching” in addiction treatment: A prospective study in 4 programs. Archives of General Psychiatry. 1997;54(8):730–735. [PubMed: 9283508]
  402. McLellan A T, Hagan T A, Levine M, Meyers K, Gould F, Bencivengo M, Durell J, Jaffe J. Does clinical case management improve outpatient addiction treatment? Drug and Alcohol Dependence. 1999;55(12):91–103. [PubMed: 10402154]
  403. McLellan A T, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment. 1992;9(3):199–213. [PubMed: 1334156]
  404. McLellan A T, Lewis D C, O'Brien C P, Kleber H D. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689–1695. [PubMed: 11015800]
  405. Mee-Lee D, Gartner L, Miller M, Shulman G, Wilford B eds. ASAM Patient Placement Criteria for the Treatment of Substance-Related Disorders, 2d ed., Revised. Chevy Chase, MD: American Society of Addiction Medicine, 2001a.
  406. Mee-Lee, D, Shulman G D, Fishman M, Gastfried D R, Griffith J H eds. ASAM PPC-2R: ASAM Patient Placement Criteria for the Treatment of Substance-Related Disorders, 2d ed., Revised. Chevy Chase, MD: American Society for Addiction Medicine, 2001b.
  407. Metcalf L, Thomas F N, Duncan B L, Miller S D, Hubble M A. What works in solution-focused brief therapy: A qualitative analysis of client and therapist perceptions. In: Miller, S.D.; Hubble, M.A.; and Duncan, B.L., eds. Handbook of Solution-Focused Brief Therapy. San Francisco: Jossey-Bass Publishers, 1996, pp. 335–349.
  408. Metzger D S, Navaline H, Woody G E. Drug abuse treatment as AIDS prevention. Public Health Reports. 1998;113(Suppl. 1):97–106. [PMC free article: PMC1307732] [PubMed: 9722815]
  409. Michalets E L. Update: Clinically significant cytochrome P450 drug interactions. Pharmacotherapy. 1998;18(1):84–112. [PubMed: 9469685]
  410. Miller W R. Researching the spiritual dimensions of alcohol and other drug problems. Addiction. 1998;93(7):979–990. [PubMed: 9744129]
  411. Miller W R, Rollnick S eds. Motivational Interviewing: Preparing People for Change, 2d ed. New York: Guilford Press, 2002.
  412. Minkoff K. State of Arizona Service Planning Guidelines: Co-Occurring Psychiatric and Substance Disorders (edited version). Rockville, MD: Treatment Improvement Exchange, Center for Substance Abuse Treatment, November 2000. www​.treatment.org/Topics/dual.html[under Documents and Minkoff; accessed May 4, 2004].
  413. Moody D E, Crouch D J, Sakashita C D, Alburges M E, Minear K, Schulthies J E, Foltz R L. A gas chromatographic-positive ion chemical ionization-mass spectrometric method for the determination of l-alpha-acetylmethadol (LAAM), norLAAM, and dinorLAAM in plasma, urine, and tissue. Journal of Analytical Toxicology. 1995;19(6):343–351. [PubMed: 8926727]
  414. Moolchan E T, Hoffman J A. Phases of treatment: A practical approach to methadone maintenance treatment. International Journal of the Addictions. 1994;29(2):135–160. [PubMed: 8144272]
  415. Moolchan E T, Umbricht A, Epstein D. Therapeutic drug monitoring in methadone maintenance: Choosing a matrix. Journal of Addictive Diseases. 2001;20(2):55–73. [PubMed: 11318398]
  416. Moore L, Wicks J, Spiehler V, Holgate R. Gas chromatography-mass spectrometry confirmation of Cozart RapiScan saliva methadone and opiate tests. Journal of Analytical Toxicology. 2001;25(7):520–524. [PubMed: 11599594]
  417. Moran J, Mayberry C, Kinniburgh D, James D. Program monitoring for clinical practice: Specimen positivity across urine collection methods. Journal of Substance Abuse Treatment. 1995;12(3):223–226. [PubMed: 7474030]
  418. Moyers B, Moyers J. Moyers on Addiction: Close to Home[5-part television series]. New York: 13/WNET and Public Affairs Television, originally aired March 29–31, 1998. www​.pbs.org[accessed May 4, 2004].
  419. Mueller M D, Wyman J R. Study sheds new light on the state of drug abuse treatment nationwide. NIDA Notes. 1997;12(5):1–8.
  420. Mueser K T, Drake R E, Wallach M A. Dual diagnosis: A review of etiological theories. Addictive Behaviors. 1998;23(6):717–734. [PubMed: 9801712]
  421. Mueser K T, Rosenberg S D, Drake R E, Miles K M, Wolford G, Vidaver R, Carrieri K. Conduct disorder, antisocial personality disorder and substance use disorders in schizophrenia and major affective disorders. Journal of Studies on Alcohol. 1999;60(2):278–284. [PubMed: 10091967]
  422. Muffler J, Langrod J G, Larson D.“There is a balm in Gilead”: Religion and substance abuse treatment. In: Lowinson, J.H.; Ruiz, P.; and Millman, R., eds. Substance Abuse: A Comprehensive Textbook, 2d ed. Baltimore: Williams & Wilkins, 1992, pp. 584–595.
  423. Mulla Z D. Treatment options in the management of necrotising fasciitis caused by Group A Streptococcus. Expert Opinion in Pharmacotherapy. 2004;5(8):1695–1700. [PubMed: 15264984]
  424. Musselman D L, Kell M J. Prevalence and improvement in psychopathology in opioid dependent patients participating in methadone maintenance. Journal of Addictive Diseases. 1995;14(3):67–82. [PubMed: 8555280]
  425. Musto D F. The American Disease: Origins of Narcotic Control, 3d ed. New York: Oxford University Press, 1999.
  426. Nadelmann E, McNeeley J. Doing methadone right. The Public Interest. 1996;123:83.
  427. Najavits L M. Seeking Safety: A Treatment Manual for PTSD and Substance Abuse. New York: Guilford Press, 2002.
  428. Narcessian E J, Yoon H J. False-positive urine drug screen: Beware the poppy seed bagel [letter] Journal of Pain and Symptom Management. 1997;14(5):261–263. [PubMed: 9392917]
  429. National Center for HIV, STD and TB Prevention, Divisions of HIV/AIDS Prevention. Basic Statistics. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, 2005. www​.cdc.gov/hiv/stats.htm#exposure [accessed June 9, 2005].
  430. National Center on Addiction and Substance Abuse. Behind Bars: Substance Abuse and America's Prison Population. New York: Columbia University, January 1998.
  431. National Drug Court Institute. Methadone maintenance and other pharmacotherapeutic interventions in the treatment of opioid dependence. Drug Court Practitioner Fact Sheet 3(1), April 2002. www​.ndci.org/publications​/MethadoneFactSheet.pdf[accessed May 4, 2004].
  432. National Institute for Occupational Safety and Health (NIOSH). Violence in the Workplace: Developing and Implementing a Workplace Violence Prevention Program and Policy. Washington, DC: NIOSH, 1996, updated 1998. www​.cdc.gov/niosh/violdev.html[accessed May 4, 2004].
  433. National Institute of Neurological Disorders and Stroke. NINDS Tardive Dyskinesia Information Page. Bethesda, MD: National Institute of Neurological Disorders and Stroke, reviewed December 2001. www.ninds.nih.gov%2Fhealth_and_medical%2Fdisorders%2Ftardive_ doc.htm[accessed May 4, 2004].
  434. National Institute on Drug Abuse (NIDA). Information on LAAM: Chemistry, Pharmacology and Clinical Trials Results. Rockville, MD: Medications Development Division, NIDA, 1993a.
  435. National Institute on Drug Abuse (NIDA). Recovery Training and Self-Help: Relapse Prevention and Aftercare for Drug Addicts. NIH Publication No. 93-3521, Bethesda, MD: NIDA, 1993b.
  436. National Institute on Drug Abuse (NIDA). Principles of Drug Addiction Treatment: A Research-Based Guide. NIH Publication No. 00-4180. Rockville, MD: NIDA, 1999, reprinted 2000.
  437. National Institute on Drug Abuse (NIDA). NIDA Community Drug Alert Bulletin—Hepatitis. Rockville, MD: NIDA, 2000. www​.drugabuse.gov/HepatitisAlert​/HepatitisAlert.html#Anchor-Injection-17780 [accessed May 4, 2004].
  438. National Institute on Drug Abuse. Blending Clinical Practice and Research—Forging Partnerships To Enhance Drug Addiction Treatment. Conference Proceedings, New York, April 2002. Rockville, MD: National Institute on Drug Abuse, 2002. 165.112.78.61/whatsnew/meetings/blending2002/PlenaryDay1.html [accessed May 4, 2004].
  439. National Institutes of Health (NIH). Acupuncture. NIH Consensus Statement No. 107. 1997a;14(5):1–34.
  440. National Institutes of Health (NIH). Effective medical treatment of opiate addiction. NIH Consensus Statement. 1997b;15(6):1–38. consensus.nih.gov/cons/108/108_statement.htm#top [accessed May 4, 2004]
  441. National Institutes of Health (NIH). Management of Hepatitis C: 2002. Consensus Development Conference Statement. Rockville, MD: NIH, September 2002. consensus.nih.gov/cons/ 116/116cdc_intro.htm [accessed May 4, 2004].
  442. National Institutes of Health Consensus Development Panel. Effective medical treatment of opiate addiction. JAMA. 1998;280(22):1936–1943. [PubMed: 9851480]
  443. National Library of Medicine. Naltrexone (Systemic). MedlinePlus. Bethesda, MD: U.S. National Library of Medicine, National Institutes of Health, 1997. www.nlm.nih.gov/ medlineplus/druginfo/uspdi/202388.html[accessed May 4, 2004].
  444. Nduati R, Mbori-Ngacha D, John G, Richardson B, Kreiss J. Breastfeeding in women with HIV. JAMA. 2000;284(8):956–957. [PubMed: 10944630]
  445. Nemeroff C B, DeVane C L, Pollock B G. Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry. 1996;153(3):311–320. [PubMed: 8610817]
  446. Newman C F. Establishing and maintaining a therapeutic alliance with substance abuse patients: A cognitive therapy approach. In: Beyond the Therapeutic Alliance: Keeping the Drug-Dependent Individual in Treatment. NIDA Research Monograph 165. NIH Publication No. 97-4142. Rockville, MD: National Institute on Drug Abuse, 1997, pp. 181–206. 165.112.78.61/pdf/monographs/monograph165/181-206_Newman.pdf [accessed May 4, 2004].
  447. Noone M, Tabaqchali M, Spillane J B. Clostridium novyi causing necrotizing fasciitis in an injecting drug user. Journal of Clinical Pathology. 2002;55:141–142. [PMC free article: PMC1769578] [PubMed: 11865011]
  448. North C S, Eyrich K M, Pollio D E.“Are rates of psychiatric disorders changing over time in the homeless population?” Paper No. 24000 presented at the 129th Annual Meeting of the American Public Health Association, Atlanta, GA, October 2001.
  449. Novick D M, Joseph H, Croxson T S, Salsitz E A, Wang G, Richman B L, Poretsky L, Keefe J B, Whimbey E. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Archives of Internal Medicine. 1990;150(1):97–99. [PubMed: 2297301]
  450. Novick D M, Ochshorn M, Ghali V, Croxson T S, Mercer W D, Chiorazzi N, Kreek M J. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. Journal of Pharmacology and Experimental Therapeutics. 1989;250(2):606–610. [PubMed: 2788218]
  451. Nunes E V, Quitkin F M, Donovan S J, Deliyannides D, Ocepek-Welikson K, Koenig T, Brady R, McGrath P J, Woody G. Imipramine treatment of opiate-dependent patients with depressive disorders: A placebo-controlled trial. Archives of General Psychiatry. 1998a;55(2):153–160. [PubMed: 9477929]
  452. Nunes E V, Weissman M M, Goldstein R B, McAvay G, Seracini A M, Verdeli H, Wickramaratne P J. Psychopathology in children of parents with opiate dependence and/or major depression. Journal of the American Academy of Child and Adolescent Psychiatry. 1998b;37(11):1142–1151. [PubMed: 9808925]
  453. Nurco D N, Stephenson P, Hanlon T E. Contemporary issues in drug abuse treatment linkage with self-help groups. In: Pickens, R.W.; Leukefeld, C.G.; and Schuster, C.R., eds. Improving Drug Treatment. NIDA Research Monograph 106. DHHS Publication No. (ADM) 91-1754. Washington, DC: Supt. of Docs., U.S. Govt. Print. Off., 1991, pp. 338–348.
  454. Nyswander M. The Drug Addict as a Patient. New York: Grune and Stratton, 1956.
  455. O'Brien C P, Greenstein R A, Mintz J, Woody G E. Clinical experience with naltrexone. American Journal of Drug and Alcohol Abuse. 1975;2(34):365–377. [PubMed: 1227298]
  456. O'Brien, C P, Woody G E, McLellan A T. Enhancing the effectiveness of methadone using psychotherapeutic interventions. In: Onken, L.S.; Blaine, J.D.; and Boren, J.J., eds. Integrating Behavioral Therapies With Medication in the Treatment of Drug Dependence. NIDA Research Monograph 150. NIH Publication No. 95-3899. Rockville, MD: National Institute on Drug Abuse, 1995, pp. 5–18.
  457. O'Connor P G, Fiellin D A. Pharmacologic treatment of heroin-dependent patients. Annals of Internal Medicine. 2000;133(1):40–54. [PubMed: 10877739]
  458. Oda Y, Kharasch E D. Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): Potential contribution of intestinal metabolism to presystemic clearance and bioactivation. Journal of Pharmacology and Experimental Therapeutics. 2001;298(3):1021–1032. [PubMed: 11504799]
  459. Office of Applied Studies. Pregnant women in substance abuse treatment. DASIS Report. Rockville, MD: Substance Abuse and Mental Health Services Administration, May 17, 2002.
  460. Office of Minority Health. National Standards for Culturally and Linguistically Appropriate Services in Health Care. Rockville, MD: U.S. Department of Health and Human Services, March 2001.
  461. Office of National Drug Control Policy (ONDCP). Pulse Check: Trends in Drug Abuse, April 2002—Diverted Synthetic Opioids. Washington, DC: ONDCP, 2002. www​.whitehousedrugpolicy​.gov/publications​/drugfact/pulsechk/apr02​/synthetic%5Fopiods.html[accessed May 4, 2004].
  462. Office of National Drug Control Policy (ONDCP). The President's National Drug Control Strategy. Washington, DC: ONDCP, 2003. www​.whitehousedrugpolicy​.gov/publications​/policy/ndcs03/index.html[accessed May 4, 2004].
  463. Okruhlica L, Devinsk F, Valentova J, Klempova D. Does therapeutic threshold of methadone concentration in plasma exist? Heroin Addiction and Related Clinical Problems. 2002;4(1):29–36.
  464. Otero M J, Fuertes A, Sánchez R, Luna G. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: An alert. AIDS. 1999;13(8):1004–1005. [PubMed: 10371190]
  465. Parrino M. AATOD's Five Year Plan for Methadone Treatment in the United States. New York: American Association for the Treatment of Opioid Addiction, 2001.
  466. Parrino M. Drug Court Practitioner Fact Sheet. New York: American Association for the Treatment of Opioid Dependence, 2002. www​.compa-ny.org/mar2002.htm[accessed May 4, 2004].
  467. Paul S M, Pollet C, Burr C, Bardeguez A, Khanlou P. Prevention of perinatal HIV transmission. New Jersey Medicine. 2001;98(3):23–31. [PubMed: 11269830]
  468. Payte J T, Zweben J E. Opioid maintenance therapies. In: Graham, A.W.; Schultz, T.K.; and Wilford, B.B., eds. Principles of Addiction Medicine, 2d ed. Chevy Chase, MD: American Society of Addiction Medicine, 1998.
  469. Payte J T, Zweben J E, Martin J. Opioid maintenance treatment. In: Graham, A.W.; Schultz, T.K.; Mayo-Smith, M.F.; Ries, R.K.; and Wilford, B.B., eds. Principles of Addiction Medicine, 3d ed. Chevy Chase, MD: American Society of Addiction Medicine, 2003, pp. 751–766.
  470. Payte, T. Induction simulation—moderate to high tolerance [slide presentation]. In: Miller, S.C., and Salsitz, E.A., eds. ASAM Review Course in Addiction Medicine. Chevy Chase, MD: American Society of Addiction Medicine, 2002.
  471. Pennings E J, Leccese A P, Wolff F A. Effects of concurrent use of alcohol and cocaine. Addiction. 2002;97(7):773–783. [PubMed: 12133112]
  472. Petrakis I L, Carroll K M, Nich C, Gordon L T, McCance-Katz E F, Frankforter T, Rounsaville B J. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction. 2000;95(2):219–228. [PubMed: 10723850]
  473. Petry N M. A comprehensive guide to the application of contingency management procedures in clinical settings. Drug and Alcohol Dependence. 2000;58:9–25. [PubMed: 10669051]
  474. Petry N M, Bickel W K, Piasecki D, Marsch L A, Badger G J. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. American Journal on Addictions. 2000;9(3):265–269. [PubMed: 11000922]
  475. Piane G. Contingency contracting and systematic desensitization for heroin addicts in methadone maintenance programs. Journal of Psychoactive Drugs. 2000;32(3):311–319. [PubMed: 11061683]
  476. Piscitelli S C, Rodvold K A. Drug Interactions in Infectious Diseases. Totowa, NJ: Humana Press, 2001.
  477. Pitre U, Dansereau D F, Joe G W. Client education levels and the effectiveness of node-link maps. Journal of Addictive Diseases. 1996;15(3):27–44. [PubMed: 8842848]
  478. Pitre U, Dansereau D F, Simpson D D. The role of node-link maps in enhancing counseling efficiency. Journal of Addictive Diseases. 1997;16(3):39–49. [PubMed: 9243339]
  479. Poynard T, McHutchison J, Davis G L, Estaban-Mur R, Goodman Z, Bedossa P, Albrecht J. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology. 2000;32(5):1131–1137. [PubMed: 11050066]
  480. Prater C D, Zylstra R G, Miller K E. Successful pain management for the recovering addicted patient. Primary Care Companion to the Journal of Clinical Psychiatry. 2002;4(4):125–131. [PMC free article: PMC315480] [PubMed: 15014719]
  481. Preston K L, Huestis M A, Wong C J, Umbricht A, Goldberger B A, Cone E J. Monitoring cocaine use in substance-abuse-treatment patients by sweat and urine testing. Journal of Analytical Toxicology. 1999a;23(5):313–322. [PubMed: 10488917]
  482. Preston K L, Silverman K, Schuster C R, Cone E J. Assessment of cocaine use with quantitative urinalysis and estimation of new uses. Addiction. 1997;92(6):717–727. [PubMed: 9246799]
  483. Preston K L, Silverman K, Umbricht A, DeJesus A, Montoya I D, Schuster C R. Improvement in naltrexone treatment compliance with contingency management. Drug and Alcohol Dependence. 1999b;54(2):127–135. [PubMed: 10217552]
  484. Preston K L, Umbricht A, Epstein D H. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Archives of General Psychiatry. 2000;57(4):395–404. [PubMed: 10768702]
  485. Prochaska J O, Di Clemente C C. Transtheoretical therapy: Toward a more integrative model of change. Psychotherapy: Theory, Research and Practice. 1982;19(3):276–288.
  486. Prochaska J O, Di Clemente, C C. Toward a comprehensive model of change. In: Miller, W.R., and Heather, N., eds. Treating Addictive Behaviors: Processes of Change. New York: Plenum Press, 1986, pp. 3–27.
  487. Prochaska J O, Di Clemente C C, Norcross J C. In search of how people change: Applications to addictive disorders. American Psychologist. 1992;47(9):1102–1114. [PubMed: 1329589]
  488. Ranger-Rogez S, Alain S, Denis F. Hepatitis viruses: Mother to child transmission. Pathologie-Biologie (Paris). 2002;50(9):568–575. [PubMed: 12490422]
  489. Rao S, Schottenfeld R. Methadone maintenance. In: Ott, P.J.; Tartar, R.E.; and Ammerman, R.T., eds. Sourcebook on Substance Abuse: Etiology, Epidemiology, Assessment, and Treatment. Boston: Allyn & Bacon, 1999, pp. 362–372.
  490. Rawson R A, Huber A, McCann M, Shoptaw S, Farabee D, Reiber C, Ling W. A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Archives of General Psychiatry. 2002;59(9):817–824. [PubMed: 12215081]
  491. Regev A, Jeffers L J. Hepatitis C and alcohol. Alcoholism, Clinical and Experimental Research. 1999;23(9):1543–1551. [PubMed: 10512322]
  492. Regier D A, Farmer M E, Rae D S, Locke B Z, Keith S J, Judd L L, Goodwin F K. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) study. JAMA. 1990;264(19):2511–2518. [PubMed: 2232018]
  493. Reid J. Substance Abuse and the American Woman. New York: National Center on Addiction and Substance Abuse at Columbia University, 1996.
  494. Reilly P M, Shopshire M S. Anger Management for Substance Abuse and Mental Health Clients: A Cognitive Behavioral Therapy Manual. DHHS Publication No. (SMA) 02-3756. Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 2002.
  495. Reilly P M, Shopshire M S, Durazzo T C, Campbell, T A. Anger Management for Substance Abuse and Mental Health Clients: Participant Workbook. DHHS Publication No. (SMA) 02-3662. Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 2002.
  496. Reynaud M, Tracqui A, Petit G, Potard D, Courty P. Six deaths linked to misuse of buprenorphine-benzodiazepine combinations. American Journal of Psychiatry. 1998;155:448–449. [PubMed: 9501765]
  497. Rhoades H M, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: Methadone dose and visit frequency. American Journal of Public Health. 1998;88(1):34–39. [PMC free article: PMC1508390] [PubMed: 9584030]
  498. Roberts E A, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology. 2002;36(5 Suppl. 1):S106–S113. [PubMed: 12407583]
  499. Robins L N, Locke B Z, Regier, D A. An overview of psychiatric disorders in America. In: Robins, L.N., and Regier, D.A., eds. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York: Free Press, 1991, pp. 328–366.
  500. Robles E, Silverman K, Stitzer M L. Contingency management therapies. In: Strain, E.C., and Stitzer, M.L., eds. Methadone Treatment for Opioid Dependence. Baltimore: Johns Hopkins University Press, 1999, pp. 196–222.
  501. Romans S E, Poore M R, Martin J L. The perpetrators of domestic violence. Medical Journal of Australia. 2000;173:484–488. [PubMed: 11149306]
  502. Room R. The Co-Occurrence of Mental Disorders and Addictions: Evidence on Epidemiology, Utilization, and Treatment Outcomes. ARF Research Document Series No. 141. Toronto, Canada: Addiction Research Foundation Division, Addiction and Mental Health Services Corporation, 1998.
  503. Rosen T S, Johnson H L. Children of methadone maintained mothers: Follow-up to 18 months of age. Journal of Pediatrics. 1982;101(2):192–196. [PubMed: 6178811]
  504. Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy R K. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003;289(18):2370–2379. [PubMed: 12746360]
  505. Rosenblum A, Magura S, Foote J, Palij M, Handelsman L, Lovejoy M, Stimmel B. Treatment intensity and reduction in drug use for cocaine-dependent methadone patients: A dose-response relationship. Journal of Psychoactive Drugs. 1995;27(2):151–159. [PubMed: 7562262]
  506. Ross J, Darke S. The nature of benzodiazepine dependence among heroin users in Sydney, Australia. Addiction. 2000;95(12):1785–1793. [PubMed: 11177494]
  507. Rothenberg J L, Sullivan M A, Church S H, Seracini A, Collins E, Kleber H D, Nunes E V. Behavioral naltrexone therapy: An integrated treatment for opiate dependence. Journal of Substance Abuse Treatment. 2002;23(4):351–360. [PubMed: 12495797]
  508. Rounsaville B J, Kosten T R, Weissmann M M, Kleber H D. Prognostic significance of psychopathology in treated opiate addicts: A 2.5-year follow-up study. Archives of General Psychiatry. 1986;43(8):739–745. [PubMed: 3729668]
  509. Rowan-Szal G A, Chatham L R, Joe G W, Simpson D D. Services provided during methadone treatment: A gender comparison. Journal of Substance Abuse Treatment. 2000a;19(1):7–14. [PubMed: 10867295]
  510. Rowan-Szal G A, Chatham L R, Simpson D D. Importance of identifying cocaine and alcohol dependent methadone clients. American Journal on Addictions. 2000b;9(1):38–50. [PubMed: 10914292]
  511. Roxane Laboratories, Inc. ORLAAM®: Levomethadyl Acetate Hydrochloride Oral Solution. [package insert]. Columbus, OH: Roxane Laboratories, Inc., revised May 2001.
  512. Ryan F. Detected, selected, and sometimes neglected: Cognitive processing of cues in addiction. Experimental and Clinical Psychopharmacology. 2002;10(2):67–76. [PubMed: 12022800]
  513. Saada M, Le Chenadec J, Berrebi A, Bongain A, Delfraissy J F, Mayaux M J, Meyer L. Pregnancy and progression to AIDS: Results of the French prospective cohorts. AIDS. 2000;14(15):2355–2360. [PubMed: 11089624]
  514. Saadeh S, Cammell G, Carey W D, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology. 2001;33(1):196–200. [PubMed: 11124836]
  515. Salsitz E A, Joseph H, Frank B, Perez J, Richman B L, Solomon N, Kalin M F, Novick D M. Methadone medical maintenance (MMM): Treating chronic opioid dependence in private medical practice—a summary report (1983-1998). Mount Sinai Journal of Medicine. 2000;67(56):388–397. [PubMed: 11064489]
  516. Sandberg G G, Marlatt G A. Relapse prevention. In: Ciraulo, D.A., and Shader, R.I., eds. Clinical Manual of Chemical Dependence. Washington, DC: American Psychiatric Press, 1991, pp. 377–399.
  517. Saunders B, Wilkinson C, Phillips M. The impact of a brief motivational intervention with opiate users attending a methadone programme. Addiction. 1995;90(3):415–424. [PubMed: 7735025]
  518. Savage S R. Principles of pain treatment in the addicted patient. In: Graham, A.W.; Schultz, T.K.; and Wilford, B.B., eds. Principles of Addiction Medicine, 2d ed. Chevy Chase, MD: American Society of Addiction Medicine, 1998, pp. 109–134.
  519. Savage S R. Opioid use in the management of chronic pain. Medical Clinics of North America. 1999;83(3):761–785. [PubMed: 10386124]
  520. Saxon A J, Calsyn D A, Haver V M, Erickson L. A nationwide survey of urinalysis practices of methadone maintenance clinics: Utilization of laboratory services. Archives of Pathology and Laboratory Medicine. 1990;114(1):94–100. [PubMed: 2294873]
  521. Schiff M, El-Bassel N, Engstrom M, Gilbert L. Psychological distress and intimate physical and sexual abuse among women in methadone maintenance treatment programs. Social Service Review. 2002;76(2):302–320.
  522. Schindler S D, Eder H, Ortner R, Rohrmeister K, Langer M, Fischer G. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction. 2003;98(1):103–110. [PubMed: 12492761]
  523. Schmoke K L. Medicalizing the war on drugs. Academic Medicine. 1995;70(5):355–358. [PubMed: 7748378]
  524. Schobelock, M J. Product Discontinuation Notice: ORLAAM (Levomethadyl hydrochloride acetate) Oral Solution, 10 mg/ml, CII NDC 0054-3649-63. Columbus, OH: Roxane Laboratories, Inc., 2003.
  525. Schwartz R P, Brooner R K, Montoya I D, Currens M, Hayes M. A 12-year follow-up of a methadone medical maintenance program. American Journal on Addictions. 1999;8(4):293–299. [PubMed: 10598212]
  526. Schwetz B A. Labeling changes for ORLAAM. JAMA. 2001;285(21):2705. [PubMed: 11386912]
  527. Scimeca M M, Savage S R, Portenoy R, Lowinson J. Treatment of pain in methadone-maintained patients. Mount Sinai Journal of Medicine. 2000;67(56):412–422. [PubMed: 11064492]
  528. Self D W, Nestler E J. Relapse to drug-seeking: Neural and molecular mechanisms. Drug and Alcohol Dependence. 1998;51(12):49–60. [PubMed: 9716929]
  529. Sellers E M, Ciraulo D A, DuPont R L, Griffiths R R, Kosten T R, Romach M K, Woody G E. Alprazolam and benzodiazepine dependence. Journal of Clinical Psychiatry. 1993;54(Suppl.):64–77. [PubMed: 8262891]
  530. Selwyn P A, Budner N S, Wasserman W C, Arno P S. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Public Health Reports. 1993;108(4):492–500. [PMC free article: PMC1403415] [PubMed: 8393579]
  531. Shepard S. Proposed methadone clinics draw fire. Memphis Business Journal. 2001;13(51):1.
  532. Shoptaw S, Jarvik M E, Ling W, Rawson R A. Contingency management for tobacco smoking in methadone-maintained opiate addicts. Addictive Behaviors. 1996;21(3):409–412. [PubMed: 8883490]
  533. Siddiqui N S, Brown L S Jr, Meyer T J, Gonzalez V. Decline in HIV-1 seroprevalence and low seroconversion rate among injecting drug users at a methadone maintenance program in New York City. Journal of Psychoactive Drugs. 1993;25(3):245–250. [PubMed: 8258762]
  534. Silverman K, Chutuape M A, Bigelow G E, Stitzer M L. Voucher-based reinforcement of attendance by unemployed methadone patients in a job skills training program. Drug and Alcohol Dependence. 1996;41:197–207. [PubMed: 8842632]
  535. Silverman K, Preston K L, Stitzer M L, Schuster C R. Efficacy and versatility of voucher-based reinforcement in drug abuse treatment. In: Higgins, S., and Silverman, K., eds. Motivating Behavior Change Among Illicit-Drug Abusers: Research on Contingency Management Interventions. Washington, DC: American Psychological Association, 1999, pp. 163–181.
  536. Simpson D, Braithwaite R A, Jarvie D R, Stewart M J, Walker S, Watson I W, Widdop B. Screening for drugs of abuse (II): Cannabinoids, lysergic acid diethylamide, buprenorphine, methadone, barbiturates, benzodiazepines and other drugs. Annals of Clinical Biochemistry. 1997;34(5):460–510. [PubMed: 9293303]
  537. Simpson D D, Joe G W, Dansereau D F, Chatham L R. Strategies for improving methadone treatment process and outcomes. Journal of Drug Issues. 1997a;27(2):239–260.
  538. Simpson D D, Joe G W, Greener J M, Rowan-Szal G A. Modeling year 1 outcomes with treatment process and post-treatment social influences. Substance Use & Misuse. 2000;35(1214):1911–1930. [PubMed: 11138712]
  539. Simpson D D, Joe G W, Rowan-Szal G. Drug abuse treatment retention and process effects on follow-up outcomes. Drug and Alcohol Dependence. 1997b;47(3):227–235. [PubMed: 9306048]
  540. Sissenwein A. San Mateo County takes over methadone treatment. The Almanac June 14 2000.
  541. Smolyakov R, Riesenberg K, Schlaeffer F, Borer A, Gilad J, Peled N, Alkan M. Streptococcal septic arthritis and necrotizing fasciitis in an intravenous drug user couple sharing needles. Israel Medical Association Journal. 2002;4:302–303. [PubMed: 12001711]
  542. Sorensen J L, Bernal F. A Family Like Yours: Breaking the Patterns of Drug Abuse. San Francisco: Harper & Row, 1986.
  543. Sporer K A. Acute heroin overdose. Annals of Internal Medicine. 1999;130(7):584–590. [PubMed: 10189329]
  544. Stanton M D, Shadish W R. Outcome, attrition, and family-couples treatment for drug abuse: A meta-analysis and review of the controlled, comparative studies. Psychological Bulletin. 1997;122(2):170–191. [PubMed: 9283299]
  545. Stark M J, Campbell B K. A psychoeducational approach to methadone maintenance treatment: A survey of client reactions. Journal of Substance Abuse Treatment. 1991;8(3):125–131. [PubMed: 1960765]
  546. Stastny D, Potter M. Alcohol abuse by patients undergoing methadone treatment programmes. British Journal of Addiction. 1991;86(3):307–310. [PubMed: 2025693]
  547. Sterling R C, Gottheil E, Weinstein S P, Serota R. The effect of therapist/patient race-and sex-matching in individual treatment. Addiction. 2001;96(7):1015–1022. [PubMed: 11440612]
  548. Stine S M, Greenwald M K, Kosten T R. Pharmacologic interventions for opioid addiction. In: Graham A.W.; Schultz, T.K.; Mayo-Smith, M.F.; Ries, R.K and Wilford, B.B. eds. Principles of Addiction Medicine 3d ed. Chevy Chase, MD: American Society of Addiction Medicine, 2003, pp. 735–750.
  549. Stitzer M L, Bickel W K, Bigelow G E. Altered dose incentive procedures: Effects on polydrug use among methadone maintenance patients. In: Harris, L.S., ed. Problems of Drug Dependence, 1986: Proceedings of the 48th Annual Scientific Meeting, the Committee on Problems of Drug Dependence, Inc. NIDA Research Monograph 76. Rockville, MD: National Institute on Drug Abuse, 1986, pp.162–167.
  550. Stitzer M L, Griffiths R R, McLellan A T, Grabowski J, Hawthorne J W. Diazepam use among methadone maintenance patients: Patterns and dosages. Drug and Alcohol Dependence. 1981;8(3):189–199. [PubMed: 7327083]
  551. Stitzer M L, Iguchi M Y, Kidorf M, Bigelow G E. Contingency management in methadone treatment: The case for positive incentives. In: Orken, L.S.; Blaine, J.D.; and Boren, J.J., eds. Behavioral Treatments for Drug Abuse and Dependence. NIDA Research Monograph 137. NIH Publication No. 93-3684. Rockville, MD: National Institute on Drug Abuse, 1993, pp. 19–36. [PubMed: 8289921]
  552. Stoskopf C H, Kim Y K, Glover S H. Dual diagnosis: HIV and mental illness, a population-based study. Community Mental Health Journal. 2001;37(6):469–479. [PubMed: 11504140]
  553. Strain E C, Bigelow G E, Liebson I A, Stitzer M L. Moderate- vs. high-dose methadone in the treatment of opioid dependence: A randomized trial. JAMA. 1999;281(11):1000–1005. [PubMed: 10086434]
  554. Strauss M E, Lessen-Firestone J K, Starr R H, Ostrea E M. Behavior of narcotic-addicted newborns. Child Development. 1975;46:887–893. [PubMed: 1201667]
  555. Strauss M E, Starr R H, Ostrea E M, Chavez C J, Stryker J C. Behavioral concomitants of prenatal addiction to narcotics. Journal of Pediatrics. 1976;89(5):842–846. [PubMed: 978336]
  556. Substance Abuse and Mental Health Services Administration (SAMHSA). Facilities providing methadone/LAAM treatment to clients with opioid addiction. The DASIS Report Rockville, MD: SAMHSA, December 6, 2002a.
  557. Substance Abuse and Mental Health Services Administration (SAMHSA). Mortality Data From the Drug Abuse Warning Network, 2001. DAWN Series D-23. DHHS Publication No. (SMA) 03-3781. Rockville, MD: Office of Applied Studies, SAMHSA, 2002b.
  558. Substance Abuse and Mental Health Services Administration (SAMHSA). Report to Congress on the Prevention and Treatment of Co-Occurring Substance Abuse Disorders and Mental Disorders. Rockville, MD: SAMHSA, 2002c.
  559. Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment Episode Data Set (TEDS): 1992-2000. National Admissions to Substance Abuse Treatment Services, DASIS Series S-17. DHHS Publication No. (SMA) 02-3727. Rockville, MD: Office of Applied Studies, SAMHSA, 2002d.
  560. Substance Abuse and Mental Health Services Administration (SAMHSA). Drug Addiction Treatment Act of 2000. Rockville, MD: SAMHSA, 2003a.
  561. Substance Abuse and Mental Health Services Administration (SAMHSA). Narcotic analgesics in brief. The DAWN Report. Rockville, MD: Office of Applied Studies, SAMHSA, 2003b pp. 1–4.
  562. Substance Abuse and Mental Health Services Administration (SAMHSA). Results From the 2002 National Survey on Drug Use and Health: National Findings. NHSDA Series H-22, DHHS Publication No. (SMA) 03-3836. Rockville, MD: Office of Applied Studies, SAMHSA, 2003c.
  563. Substance Abuse and Mental Health Services Administration (SAMHSA). Strategies for Developing Treatment Programs for People With Co-Occurring Substance Abuse and Mental Disorders. SAMHSA Publication No. 3782. Rockville, MD: SAMHSA, 2003d.
  564. Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment Admissions in Urban and Rural Areas Involving Abuse of Narcotic Painkillers. Rockville, MD: Office of Applied Sciences, SAMHSA, January 2004, pp. 1–5.
  565. Substance Abuse and Mental Health Services Administration (SAMHSA). Detailed Emergency Department Tables From the Drug Abuse Warning Network 2001. Rockville, MD: Office of Applied Studies, SAMHSA, n.d.a.
  566. Substance Abuse and Mental Health Services Administration (SAMHSA). Patient Education Rockville, MD: Division of Pharmacologic Therapies, Center for Substance Abuse Treatment, SAMHSA, n.d.b. dpt​.samhsa.gov/index.htm[accessed May 4, 2004].
  567. Sullivan L E, Fiellin D A. Hepatitis C and HIV infections: Implications for clinical care in injection drug users. American Journal on Addictions. 2004;13(1):1–20. [PubMed: 14766434]
  568. Svikis D S, Golden A S, Huggins G R, Pickens R W, McCaul M E, Velez M L, Rosendale C T, Brooner R K, Gazaway P M, Stitzer M L, Ball C E. Cost-effectiveness of treatment for drug-abusing pregnant women. Drug and Alcohol Dependence. 1997a;45:105–113. [PubMed: 9179512]
  569. Svikis D S, Lee J H, Haug N A, Stitzer M L. Attendance incentives for outpatient treatment: Effects in methadone- and non-methadone-maintained pregnant drug dependent women. Drug and Alcohol Dependence. 1997b;48:33–41. [PubMed: 9330919]
  570. Swotinsky R B, Smith D R. Laboratory analysis and performance testing. In: The Medical Review Officer's Manual: Medical Review Officer Certification Council's Guide to Drug Testing. Beverly Farms, MA: OEM Press, 1999.
  571. Sylvestre D L. The impact of drug and alcohol use on hepatitis C treatment outcomes. Drug and Alcohol Dependence. 2002a;66(Suppl.):S178.
  572. Sylvestre D L. Treating hepatitis C in methadone maintenance patients: An interim analysis. Drug and Alcohol Dependence. 2002b;67(2):117–123. [PubMed: 12095661]
  573. Sylvestre D L.“Hepatitis C: How To Handle the Hogwash.” Presented at the American Association for the Treatment of Opioid Addiction Annual Meeting, Washington, DC, April 2003. Oakland, CA: Oasis, Inc., 2003. www​.oasisclinic.org[accessed May 4, 2004].
  574. Sylvestre D L, Clements B J. The impact of negative prognostic factors on hepatitis C treatment outcomes in recovering injection drug users. Hepatology. 2002;36(4):225.
  575. Tai B, Blaine J, the NIDA Treatment Workgroup Naltrexone: An Antagonist Therapy for Heroin Addiction. Meeting summary. NIDA Treatment Workgroup, November 12–13, 1997. Bethesda, MD: National Institute on Drug Abuse, 2001. www​.drugabuse.gov/MeetSum/naltrexone​.html[accessed May 4, 2004].
  576. Taylor J R, Watson I D, Tames F J, Lowe D. Detection of drug use in a methadone maintenance clinic: Sweat patches versus urine testing. Addiction. 1998;93(6):847–853. [PubMed: 9744120]
  577. Tennant F, Shannon J. Cocaine abuse in methadone maintenance patients is associated with low serum methadone concentrations. Journal of Addictive Diseases. 1995;14(1):67–74. [PubMed: 7632748]
  578. Thomas D L, Astemborski J, Rai R M, Anania F A, Schaeffer M, Galai N, Nolt K, Nelson K E, Strathdee S A, Johnson L, Laeyendecker O, Boitnott J, Wilson L E, Vlahov D. The natural history of hepatitis C virus infection: Host, viral and environmental factors. JAMA. 2000;284(4):450–456. [PubMed: 10904508]
  579. Thomas D L, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, Nelson K E. Correlates of hepatitis C virus infections among injection drug users. Medicine. 1995;74(4):212–220. [PubMed: 7623656]
  580. Thomas J. Drug injectors sharing cookers and cotton increase their risk of hepatitis C. NIDA Notes 16(3):9–11, 2001. www​.drugabuse.gov/NIDA_Notes​/NNVol16N3/Drug.html[accessed May 4, 2004].
  581. Titsas A, Ferguson M M. Impact of opioid use on dentistry. Australian Dental Journal. 2002;47(2):94–98. [PubMed: 12139280]
  582. Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: A report on 20 fatalities. Journal of Analytical Toxicology. 1998a;22:430–434. [PubMed: 9788517]
  583. Tracqui A, Tournoud C, Flesch F, Kopferschmitt J, Klintz P, Deveaux M, Ghysel M H, Marquet P, Pepin G, Petit G, Jaeger A, Ludes B. [Acute poisoning during substitution therapy based on high-dosage buprenorphine: 29 clinical cases—20 total cases] La Presse Médicale. 1998b;27(12):557–561. [PubMed: 9767947]
  584. Turner C F, Rogers S M, Miller H G, Miller W C, Gribble J N, Chromy J R, Leone P A, Cooley P C, Quinn T C, Zenilman J M. Untreated gonococcal and chlamydial infection in a probability sample of adults. JAMA. 2002;287(6):726–733. [PubMed: 11851539]
  585. Umbricht-Schneiter A, Ginn D H, Pabst K M, Bigelow G E. Providing medical care to methadone clinic patients: Referral vs on-site care. American Journal of Public Health. 1994;84(2):207–210. [PMC free article: PMC1615007] [PubMed: 8296941]
  586. U.S. Department of Health and Human Services (DHHS), Office of Minority Health. National Standards for Culturally and Linguistically Appropriate Services in Health Care. Rockville, MD: DHHS, March 2001.
  587. U.S. Department of Justice, Office of Justice Programs, Bureau of Justice Statistics (BJS). Special Report: Substance Abuse and Treatment, State and Federal Prisoners, 1997. NCJ 172871. Rockville, MD: BJS, January 1999. www​.ojp.usdoj.gov/bjs/pub/pdf/satsfp97​.pdf[accessed May 4, 2004].
  588. Vannicelli M. Removing the Roadblocks: Group Psychotherapy With Substance Abusers and Family Members. New York: Guilford Press, 1992.
  589. Verebey K, Buchan B J, Turner C E. Laboratory testing. In: Frances, R.J., and Miller, S.I., eds. Clinical Textbook of Addictive Disorders, 2d ed. New York: Guilford Press, 1998, p. 80.
  590. Villagomez R E, Meyer T J, Lin M M, Brown L S Jr. Post-traumatic stress disorder among inner city methadone maintenance patients. Journal of Substance Abuse Treatment. 1995;12(4):253–257. [PubMed: 8830152]
  591. Villano C L, Rosenblum A, Magura S, Fong C. Improving treatment engagement and outcomes for cocaine-using methadone patients. American Journal of Drug and Alcohol Abuse. 2002;28(2):213–230. [PubMed: 12014813]
  592. Vincent F, Bessard J, Vacheron J, Mallaret M, Bessard G. Determination of buprenorphine and norbuprenorphine in urine and hair by gas chromatography-mass spectrometry. Journal of Analytical Toxicology. 1999;23(4):270–279. [PubMed: 10445490]
  593. Vythilingum G, Stein D J, Soifer S. Is “shy bladder syndrome” a subtype of social anxiety disorder? A survey of people with paruresis. Depression and Anxiety. 2002;16(2):84–87. [PubMed: 12219340]
  594. Walsh S L, Johnson R E, Cone E J, Bigelow G E. Intravenous and oral l-alpha-acetylmethadol: Pharmacodynamics and pharmacokinetics in humans. Journal of Pharmacology and Experimental Therapeutics. 1998;285(1):71–82. [PubMed: 9535996]
  595. Walsh S L, Preston K L, Stitzer M L, Cone E J, Bigelow G E. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology and Therapeutics. 1994;55(5):569–580. [PubMed: 8181201]
  596. Ward J, Mattick R P, Hall, W. Methadone maintenance during pregnancy. In: Ward, J.; Mattick, R.P.; and Hall, W., eds. Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Amsterdam: Harwood Academic Publishers, 1998a, pp. 397–417.
  597. Ward, J, Mattick R P, Hall, W. Psychiatric comorbidity among the opioid dependent. In: Ward, J.; Mattick R.P.; and Hall, W., eds. Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Amsterdam: Harwood Academic Publishers, 1998b, pp. 419–440.
  598. Warner E A. Laboratory diagnosis. In: Graham, A.W.; Schultz, T.K.; Mayo-Smith, M.F.; Ries, R.K.; and Wilford, B.B., eds. Principles of Addiction Treatment, 3d ed. Chevy Chase, MD: American Society of Addiction Medicine, 2003, p. 343.
  599. Washton A M. Preventing relapse to cocaine. Journal of Clinical Psychiatry. 1988;49(Suppl.):34–38. [PubMed: 3257487]
  600. Wasserman D, Weinstein M, Havassy B E, Hall S M. Factors associated with lapses to heroin use during methadone maintenance. Drug and Alcohol Dependence. 1998;52(3):183–192. [PubMed: 9839144]
  601. Weaver M F. Perinatal addiction. In: Graham, A.W.; Schultz, T.K.; Mayo-Smith, M.F.; Ries, R.K.; and Wilford, B.B., eds. Principles of Addiction Medicine, 3d ed. Chevy Chase, MD: American Society of Addiction Medicine, 2003, pp. 1231–1246.
  602. Weber E M, Cowie R. Siting Drug and Alcohol Programs: Legal Challenges to the “NIMBY” Syndrome. Technical Assistance Publication (TAP) Series 14. DHHS Publication No. (SMA) 95-3050. Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 1995.
  603. Weisner C, Mertens J, Parthasarathy S, Moore C, Lu Y. Integrating primary medical care with addiction treatment: A randomized controlled trial. JAMA. 2001;286(14):1715–1723. [PMC free article: PMC3056510] [PubMed: 11594896]
  604. Werner S B, Passaro D, McGee J, Schechter R, Vugia D J. Wound botulism in California, 1951-1998: Recent epidemic in heroin injectors. Clinical Infectious Diseases. 2000;31:1018–1024. [PubMed: 11049786]
  605. White J M, Danz C, Kneebone J, La Vincente S F, Newcombe D.A, Ali R L. Relationship between LAAM-methadone preference and treatment outcomes. Drug and Alcohol Dependence. 2002;66(3):295–301. [PubMed: 12062464]
  606. White J M, Irvine R J. Mechanisms of fatal opioid overdose. Addiction. 1999;94(7):961–972. [PubMed: 10707430]
  607. White W L. Slaying the Dragon: The History of Addiction Treatment and Recovery in America. Bloomington, IL: Chestnut Health Systems/Lighthouse Institute, 1998.
  608. Widman M, Platt J J, Lidz V, Mathis D A, Metzger D S. Patterns of service use and treatment involvement of methadone maintenance patients. Journal of Substance Abuse Treatment. 1997;14(1):29–35. [PubMed: 9218234]
  609. Wojnar-Horton R E, Kristensen J H, Yapp P, Ilett K F, Dusci L J, Hackett L P. Methadone distribution and excretion into breast milk of clients in a methadone maintenance program. British Journal of Clinical Pharmacology. 1997;44:543–547. [PMC free article: PMC2042880] [PubMed: 9431829]
  610. Wolff K, Farrell M, Marsden J, Monteiro M G, Ali R, Welch S, Strang J. A review of biological indicators of illicit drug use: Practical considerations and clinical usefulness. Addiction. 1999;94(9):1279–1298. [PubMed: 10615715]
  611. Wolff K, Hay A, Raistrick D. High-dose methadone and the need for drug measurements in plasma. Clinical Chemistry. 1991;37(9):1651–1654. [PubMed: 1654235]
  612. Woods J. Methadone advocacy: The voice of the patient. Mount Sinai Journal of Medicine. 2001;68(1):75–78. [PubMed: 11135509]
  613. Woody G E. Research findings on psychotherapy of addictive disorders. American Journal on Addictions. 2003;12(Suppl. 2):S19–S26. [PubMed: 12857660]
  614. Woody G E, Cacciola J. Review of remission criteria. In: Widiger, T.; Frances, A.; Pincus, H.; First, M.; Ross, R.; and Davis, W., eds. DSM-IV Sourcebook, Volume 1. Washington, DC: American Psychiatric Association, 1994, pp. 67–80.
  615. Woody, G E, McLellan A T, Bedrick J. Dual diagnosis. In: Kleber, H., ed. Review of Psychiatry, Volume 14. Washington, DC: American Psychiatric Association, pp. 83–104, 1995a.
  616. Woody G E, McLellan A.T, Luborsky L, O'Brien C P. Psychotherapy in community methadone programs: A validation study. American Journal of Psychiatry. 1995b;152(9):1302–1308. [PubMed: 7653685]
  617. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992.
  618. Zador D, Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. Addiction. 2000;95(1):77–84. [PubMed: 10723832]
  619. Zanis D A, Coviello D. A case study of employment case management with chronically unemployed methadone maintained clients. Journal of Psychoactive Drugs. 2001;33(1):67–73. [PubMed: 11333003]
  620. Zanis D A, McLellan A T, Alterman A I, Cnaan R A. Efficacy of enhanced outreach counseling to reenroll high-risk drug users 1 year after discharge from treatment. American Journal of Psychiatry. 1996;153(8):1095–1096. [PubMed: 8678182]
  621. Zanis D A, McLellan A T, Randall M. Can you trust patient self-reports of drug use during treatment? Drug and Alcohol Dependence. 1994;35(2):127–132. [PubMed: 8055734]
  622. Zanis D A, Woody G E. One-year mortality rates following methadone treatment discharge. Drug and Alcohol Dependence. 1998;52:257–260. [PubMed: 9839152]
  623. Zoning fight over Michigan clinic leads to a restrictive proposal. Alcoholism and Drug Abuse Weekly 10(21):3, 1998.
  624. Zweben J E. Counseling issues in methadone maintenance treatment. Journal of Psychoactive Drugs. 1991;23(2):177–190. [PubMed: 1765891]
  625. Zweben J E. Integrating psychosocial services with pharmacotherapies in the treatment of co-occurring disorders. In: Graham, A.W.; Schultz, T.K.; Mayo-Smith, M.F.; Ries, R.K.; and Wilford, B.B., eds. Principles of Addiction Medicine, 3d ed. Chevy Chase, MD: American Society of Addiction Medicine, 2003, pp. 1371–1380.

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.5M)

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...